Consensus Report

Nutrition in patients with cystic fibrosis: a European Consensus[☆]

M. Sinaasappel[a,]*, M. Stern[b], J. Littlewood[c], S. Wolfe[c], G. Steinkamp[d], Harry G.M. Heijerman[e], E. Robberecht[f], G. Döring[g]

[a]*Department of Paediatric Gastroenterology, Erasmus Medical Centre, Rotterdam, The Netherlands*
[b]*Department of Paediatrics, University of Tübingen, Tübingen, Germany*
[c]*Regional Paediatric Cystic Fibrosis Unit, St James University Hospital, Leeds, UK*
[d]*Department of Paediatrics and Paediatric Pulmonology, Medizinische Hochschule, Hannover, Germany*
[e]*Ziekenhuis Leyenburg, The Hague, The Netherlands*
[f]*Department of Paediatrics, University of Ghent, Ghent, Belgium*
[g]*Hygiene-institut University of Tübingen, Tübingen, Germany*

Abstract

This document is the result of an European Consensus conference which took place in Artimino, Tuscany, Italy, in March 2001 involving 33 experts on nutrition in patients with cystic fibrosis, organised by the European Cystic Fibrosis Society, and sponsored by Axcan-Scandipharm, Baxter, Dr Falk Pharma, Fresenius, Nutricia, SHS International, Solvay Pharmaceuticals (major sponsor). The purpose of the conference was to develop a consensus document on nutrition in patients with cystic fibrosis based on current evidence. © 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.

Keywords: European Consensus; Document; Cystic fibrosis

1. Introduction

Cystic fibrosis (CF) is a world-wide disease occurring in virtually all ethnic groups. In Caucasians it is the most common lethal hereditary disorder with autosomal recessive inheritance [1]. Approximately 1 in 25 are heterozygous carriers, while the incidence of clinical disease is approximately 1 in 2500 live births [1]. The condition is caused by mutations in a single gene of chromosome 7, which encodes the CF transmembrane conductance regulator (CFTR) [2]. The CFTR protein is a membrane bound cAMP-regulated chloride channel, which is thought to regulate other cell membrane ion channels [3]. More than 1000 different mutations have been identified so far; however, a deletion of phenylalanine in the amino acid position 508 is present in approximately 66% of chromosomes of all patients with CF world-wide.

CFTR mutations affect epithelial ion and water transport mainly in cells in the respiratory, gastrointestinal, hepatobiliary, reproductive tracts and sweat glands. The lack of chloride secretion in the pancreatic duct is responsible for obstruction and autodigestion of the pancreas early in embryonic life leading to severe exocrine pancreatic insufficiency in approximately 85% of CF newborns. In addition, intestinal obstruction complicates the neonatal period in 10–15% of the infants. Both inadequately treated pancreatic insufficiency and intestinal obstruction were held responsible for a high morbidity and mortality rate in patients with CF before

1970. As a result of various factors including better neonatal care, surgery, antibiotic treatment of pulmonary complications and improved nutrition, the median survival time of the patients has increased over the last three decades from 10 to 30 years. Nevertheless, it is still not clear to what extent improved nutritional status contributes to increased survival. In a recent report wasting was shown to be a significant predictor of survival in patients with CF independent of lung function, arterial blood oxygen and carbon dioxide tensions [4]. The fact that there is a remarkably close relationship between body weight and lung function and that terminal patients with CF are almost always severely malnourished, suggests that good nutritional care is of benefit for the patient with cystic fibrosis.

2. Nutritional deficiencies in CF

2.1. Nutrition and growth of individuals with CF

2.1.1. Growth during infancy

The mean birth weight of CF populations has been reported as subnormal (CF males: 3.18 kg, females: 3.04 kg; unaffected males: 3.37 kg, females: 3.25 kg) [5]. However, others have failed to confirm the finding of lower birth weights in CF [6,7].

Another study found children with CF to have a reduced length (-1.24 standard deviation, S.D.) weight (-0.72 S.D.) and head circumferences (-1.82 S.D.) compared with controls [8]. However, these data may not be representative since 34.6% of the infants were affected by meconium ileus, which is associated with worse outcomes [8].

The early growth pattern of infants with CF is dependent on both the age at diagnosis and the quality of the subsequent treatment they receive. The majority have pancreatic insufficiency and experience early gastrointestinal symptoms, which if not adequately treated can lead to subnormal weight gain. Even some infants diagnosed by neonatal screening have subnormal growth throughout the first year if the start of treatment is delayed by more than a few weeks after birth [9].

2.1.2. Growth after infancy

Subsequent growth velocity of CF infants is usually normal if chest infections are prevented or effectively treated and the intestinal malabsorption is adequately treated [6,7]. Almost normal growth and weight gain was maintained throughout childhood in Canadian patients with CF [10] and in 51 Swedish children with CF height gain was normal between 5 and 8 years [11]. The authors conclude that subnormal growth in infancy can be compensated for by catch-up growth thereafter. In Australian patients growth, weight and respiratory function were better at the age of 10 years in a group

of screened patients than in those born before screening was introduced [12].

As a consequence of patient registries, data from larger numbers of patients with CF are available for epidemiological investigations. In 1998 the Cystic Fibrosis Foundation (CFF) reported that 12.7% of children and 21.6% of adults were below 85% weight for height [13]. Comparable median centile values for Canadian and American patients with CF were: for height 28 and 21, respectively, weight 27 and 22, respectively, but both were 103% of ideal weight for height [14]. Data from the UK CF registry revealed that the mean weight S.D. scores of the males were between -0.25 and -0.5 until the age of 10 years after which they declined as did the body mass index (BMI). The mean weight S.D. scores of females were approximately -0.5 but they had a declining BMI after the age of 5 years [15,16]. After 10 years there was a progressive decline in SD scores for both height and weight. This deterioration in S.D. scores after the age of 10 years could be explained by some delay in the onset of puberty. However, it is more likely to be a reflection of an overall deterioration associated with an increase in the severity of the pulmonary disease.

It is increasingly apparent that the condition of the patients is closely related to the treatment they receive and that patients may be in a better nutritional state in clinics where regular attention is paid to nutrition and growth. It is encouraging that the nutritional state of new patients with CF has steadily improved over the years [17].

2.1.3. Delayed puberty and growth spurt

There is delay in the onset of puberty and menarche in patients with CF who have significant nutritional problems [18–20]; even in well-nourished females some delay has been reported [19]. Surprisingly the delay in skeletal maturation is modest in most patients with CF and seems to increase with age, as pulmonary problems become more severe [5].

3. Malnutrition: definition and assessment

3.1. Evaluation of nutrition and growth: anthropometry

3.1.1. Weight and height

The patient should see an experienced doctor at every visit and the specialist CF dietician at most clinic visits and always if weight progress is unsatisfactory [21,22]. Weight and height should be accurately measured at each clinic attendance by trained clinic staff [23]; these measurements should be charted to assess progress and compared to reference values [24–27]. Caution should be exercised when different anthropometric standards are compared [28]. Values are expressed either as (per)centiles, as percentage of the normal values for age or as standard deviation (S.D.) or Z scores. Percentage weight for height, weight for age and height for age are often used when expressing the nutritional status of children and are preferred to body mass index (BMI). The measurements are calculated from the standard equation:

$$\frac{\text{Current weight (kg)}}{\text{Weight (kg) equivalent to current height percentile}} \times 100$$

When considering S.D. scores, for a population whose values are normally distributed, the relationship of percentiles and S.D. scores are as follows: -2.0 S.D. (2.28th centile), 0 S.D. (50th centile), $+2.0$ S.D. (97.72nd centile) [24].

3.1.2. The body mass index (BMI)

The BMI (weight [kg]/height [m²]) shows a reasonable correlation to body fat mass in adults, but less so in children, and is in the first place used to quantify obesity. Some adult CF clinics use BMI as a measure of nutritional state in their patients whose growth has ceased. Recently BMI categories for adults have been redefined as underweight (<18.5), ideal (18.5–24.9), pre-obese (25.0–29.9) and obese (≥ 30.0) [29]. In children BMI values must be interpreted on the basis of comparison with age and gender specific reference centiles [30] or S.D. scores. A low BMI without deficient fatness will be found in patients with proportionately long limbs and a short trunk, where there is poor musculature or in adolescents with delayed puberty [24]. In children and adolescents, no advantage has been shown of using BMI, rather than weight for height, for documenting malnutrition.

3.1.3. Other measurements

The mid upper arm circumference and skinfold measurements [31] are held inappropriate for the detailed monitoring required in CF [32]. Noting the stages of breast, pubic hair and genital development and recording the age of the menarche in girls are important as a measure of the stage of development [25] for the correct interpretation of changes in weight and height gain during adolescence. Thus, after the age of 10 years knowledge of the puberty state is required to adequately assess growth and nutrition. More sophisticated methods of measuring body composition, that are used primarily for research purposes, offer more accurate assessment of nutritional status and growth response to nutritional therapy. These methods include total body potassium [33,34], total body electrical conductivity, bioelectrical impedance analysis [35], total body water by isotope dilution and dual energy X-ray absorptiometry [36]. Osteopenia and osteoporosis have been described in both adults and children with CF [37,38]. Bone mineral

Table 1
Guidelines for nutritional intervention. In case of malnutrition or weight loss there should be a full re-evaluation of all possible causes that affect nutritional state. If nutritional intervention is indicated the following guidelines can be used. First enhance nutritional density/optimal intake before starting supplements

	<2 years	2–18 years	>18 years
Normal nutritional state Preventive counselling	% wt./ht 90–110	% wt./ht 90–110	BMI 18.5–25 or no recent wt. loss
Dietetic referral indicated Consider supplements	Any degree of failure to thrive	%wt./ht 85–89 or wt. loss over 4-6 months or plateau in wt over 6 months	BMI <18.5 or 5% wt. loss over <2 months
Invasive nutritional support	Failure to thrive despite oral supplementation	Supplements tried and either: %wt./ht <85 or wt. falling 2 centile positions	Supplements tried and either: BMI <18.5 or >5% wt. loss over <2 months

For all age categories pay special attention if stunting is evident as defined: (1) height centile <0.4th; (2) Ht/age <90%.

density (BMD) is best determined by dual energy X-ray absorptiometry (DEXA). DEXA scans, which can simultaneously assess fat mass and lean body mass, can be carried out in most major CF units, and should be considered as part of the nutritional assessment in all patients over the age of 10 years, but there is no documented evidence of the benefit of regular DEXA scans that are followed by targeted intervention.

3.1.4. Rate of weight gain and growth

The weight for height should remain above 90% and ideally should be over 95%. Oral energy supplements are usually advised if the weight for height is between 85 and 90% in children or the BMI is less than 18.5 in adults and enteral tube feeding if weight for height falls below 85% or BMI is less than 18.5, despite trying oral energy supplements (see Table 1). Other causes of abnormal nutrition and growth include either gastrointestinal disorders such as food intolerance, coeliac disease or inflammatory bowel disease [39] or even endocrine disorders [40]. Oral or long-term inhaled steroid therapy [41] may cause a slowing of height gain in the presence of apparently normal or excessive weight gain.

3.2. Laboratory investigations

A variety of investigations may be helpful in the assessment of the patient's nutritional state [42], such as haemoglobin, total white cell and neutrophil count, serum albumin and/or pre-albumin. Urea and electrolytes should be checked whenever clinical progress is not entirely satisfactory to identify salt depletion and pseudo-Bartter's syndrome, which may cause significant growth failure [43]. Besides an ultrasound examination of the liver and upper abdomen, plasma fat-soluble vitamin A, D and E levels should be measured annually.

3.3. Definition of malnutrition

Malnutrition is defined as a weight for height value below 90% in children or as BMI below 18.5 in adults.

4. Factors contributing to malnutrition in CF

4.1. Features of malabsorption in CF patients

Malabsorption is characterised by foul smelling loose pale stools. Infants identified through newborn screening exhibit intestinal malabsorption which is of early onset and severe and if left untreated leads to severe malnutrition and growth failure [44]. Newly diagnosed children and adults may have untreated malabsorption and should be evaluated. Due to the progressive nature of the pancreatic damage, pancreatic sufficient patients [45] may eventually develop pancreatic insufficiency [46]. Malabsorption of fat and nitrogen is severe without enzyme treatment; nonetheless, some 40–50% of ingested dietary fat is absorbed without treatment. This is probably due to the action of lingual and gastric lipase [47]. Carbohydrate malabsorption is minimal [48]. Even when clinical symptoms appear to be controlled by pancreatic enzyme supplementation, many patients still have a significant degree of fat malabsorption. Thus, the control of gastrointestinal signs and symptoms is not always indicative that malabsorption is controlled. Equally, persisting abdominal signs and symptoms in the face of apparently reasonable doses of enzymes may not be due to inadequate enzyme treatment but some other cause such as constipation [39].

4.1.1. Factors other than enzyme deficiency contributing to malabsorption

Deficiency of pancreatic enzymes is the most important, but not the only factor, responsible for malabsorption in CF [49]. A further important consequence of the severe pancreatic damage is deficiency of pancreatic bicarbonate resulting in diminished capacity to buffer influxes of gastric acid into the duodenum [50]. This results in reduced efficacy of endogenous and exogenous pancreatic enzymes and precipitation of bile salts [51,52]. Bile salt replacement contains a relative reduction in taurine-conjugated and an increase in glycine-conjugated bile salts [53], the latter being less effective

at lipid solubilisation. Mucosal ion transport abnormalities resulting from deficiency of intestinal CFTR affect both water and electrolyte transport [54]. In an acid medium fatty acids, which are formed by fat digestion at the oil/water interphase, are not converted into soaps but occur in the protonated form. In this form, they are not transferred to the micellar phase but remain in the oil phase. This may further hamper fat digestion as under these conditions pancreatic lipase may catalyse the formation of triglycerides out of their digestion products. There may also be impaired mucosal uptake and transport of long chain fatty acids [55] as well as altered motility with an increase in small bowel transit time [56]. A variety of structural abnormalities may result from previous gastrointestinal surgery for meconium ileus including shortened bowel, strictures at the site of previous intestinal anastomosis, malrotation and adhesions. In all patients there are histological abnormalities of the bowel wall characteristic of CF and an excess of mucus may also be relevant [57].

4.1.2. Investigation and diagnosis of malabsorption

It is important to obtain some objective evidence of both intestinal malabsorption and pancreatic abnormality in all patients with CF both to identify those who require enzyme treatment, and to monitor the success of such treatment. If there is abdominal distension, abdominal discomfort, loose oily pale stools, and the patient is malnourished it is most likely that there is intestinal malabsorption [39,58]. Demonstrating that intestinal absorption is controlled prevents unnecessary and potentially harmful increases in the enzyme dose and also prompts a search for another cause for the symptoms [22]. Poor weight gain and growth, particularly if the appetite is good, are suggestive of malabsorption. Indirect pancreatic function tests, which detect abnormalities secondary to loss of pancreatic function, such as maldigestion and consequent malabsorption, are generally employed, because they are easier to perform and less invasive than direct assessment of the secretory capacity of the exocrine pancreas

The degree of fat malabsorption is usually taken as the marker of intestinal malabsorption. The gold standard for measuring fat absorption is an assessment of the fat excretion over 3 days and its relation to dietary fat intake over the same time period. Normally the equivalent of less than 7% of the fat ingested is excreted i.e. there is over 93% fat absorption. The total faecal fat output is usually less than 7 g per day in healthy adults and less than 2 g in small children [59]. Measurement of faecal fat using near infrared spectroscopy [60] compares favourably with the routine titrimetric method [61]. As a minimum measurement of steatorrhoea, a semiquantitative estimate of faecal fat content should be made by a method of faecal microscopy or acid steatocrit, which have been validated by comparison with

quantitative measurements [62,63]. Other indirect pancreatic function tests including the determination of relatively non-biodegradable pancreatic enzymes in faeces (chymotrypsin [64] and particularly, faecal pancreatic elastase 1 [65,66]) and tests which evaluate the capacity of pancreatic enzymes to cleave specific synthetic substrates (e.g. PABA). The ^{13}carbon mixed triglyceride breath test is a safe non-invasive way of assessing fat digestion that can be used repeatedly in children [67]. However, a large inter-individual variation under condition of relatively mild fat malabsorption has recently been documented in a rat model, suggesting that this test, as most other indirect tests of pancreatic function may be particularly useful for revealing severe pancreatic insufficiency [68]. The serum concentrations of specific pancreatic enzymes (immunoreactive trypsin [69] and lipase) can be used to document residual pancreatic function.

4.2. Energy expenditure

The main factors leading to energy loss are malabsorption due to pancreatic insufficiency and inflammation. Glucosuria in diabetic patients and protein loss in large amounts of sputum may contribute to energy losses. As the energy intake is often lower than the 120–150% of the recommended daily amount, a negative energy balance is frequently seen in patients with CF. Energy requirements are determined by measuring energy expenditure. Approximately 60–70% of total energy expenditure is determined by resting energy expenditure (REE), 10–25% by physical activity, and 10% for diet-induced thermogenesis.

Energy expenditure can either be measured or calculated. Methods for quantifying energy expenditure are: (1) indirect calorimetry; (2) direct calorimetry; (3) 24-h energy expenditure with stable isotopes; and (4) the 24-h monitoring of heart rate. Intra-individual variation of direct or indirect calorimetry is approximately 3%, while the 24-h techniques have much larger variances (10–15%). If techniques for measuring energy expenditure are unavailable; (5) REE can be estimated from body size. A direct comparison of these standards and measured values revealed differences of up to ±20% in healthy individuals. For patients with CF, a specific formula has been developed which is based on the FAO/WHO/UNO equation and supplemented with disease and activity factors [21]. However, when compared with results from indirect calorimetry, this equation underestimated REE in children and infants with CF [70,71].

Many investigators report on increased REE in patients with CF [72–78]. This increased REE is not always associated with an increase in total energy expenditure, especially in stable patients with moderate pulmonary disease [79]. With few exceptions, mean

REE was reported to be increased by 7–35% in patients with CF compared with predicted values. However, a large range of values was obtained between different individuals. Impaired lung function causes a higher workload for respiratory muscles, and increased oxygen cost of breathing, causing in CF a REE twice that of controls [72]. Chronic inflammation may also be associated with higher energy expenditure and correlations with concentrations of TNFα have been reported [77]. Acute respiratory exacerbations cause an increased REE in many patients, which reverts to lower values after antibiotic therapy [74–77]. Similarly, after 2 weeks of aerosolised dornase alpha, a decline of REE was observed [78]. Some authors reported correlations with improvements of FEV_1, CRP, TNFα, or body weight, suggesting a parallel reduction in the host inflammatory and catabolic responses after treatment.

Patients homozygous for ΔF_{508} were reported in some studies to have higher mean REE [80–82], whereas other authors did not find such a relation [83,84]. Therefore, if an energy-requiring defect is present in CF, its contribution to increased REE must be small. There is a paucity of data concerning longitudinal follow-up of individual patients. In the only long-term observational trial REE was considered as an early indicator of disease severity independent of pulmonary function [81].

Beta-agonists are bronchodilators that are frequently administered in patients with CF. Salbutamol, a major drug of this class, has been shown to increase resting energy expenditure by 10% during the first hour after inhalation [85]. When administering beta-agonists several times a day, an effect on energy requirements should be considered.

4.3. Inadequate energy intake

The poor energy intake of many individuals with CF has been well documented. Although intakes in excess of 120% of the estimated average requirement are commonly advised, when the actual energy intake is measured it is often considerably less than this [86], particularly in male patients [87].

Additionally, specific muscle stimulation with anabolic medication appears to be an option. In patients with CF it has been shown that megestrol acetate, a progestagon, leads to an increased appetite, an increase in bodyweight with an increase in lean body mass and pulmonary function [88–90]. Disadvantages are the possible development of diabetes, inhibition of growth and adrenal suppression [89]. This is a subject which need further research, and because of the side effects and the limited data available, patients should only be treated with anabolic medication in clinical trials. Growth hormone has also been shown to improve growth and clinical status in pre-pubertal patients with CF [91]. Growth hormone therapy is also associated

with a number of side effect e.g. glucose intolerance. Further research is required before its use can be widely accepted in the clinical situation.

4.4. Liver disease and bile salt loss

A significant percentage of individuals with CF eventually have biochemical, ultrasound or clinical evidence of liver disease. Prevalence estimates of liver involvement in CF remain highly variable; ranging between 2% and 37% among the studies based on the largest CF series. On the other hand three prospective studies recently carried out indicate that liver disease is a relative frequent and early complication of CF. Prevalence of cirrhosis is approximately 10% [92,93]. In one third of these patients liver disease develops before the age of 5 years. Patients with CF who have overt clinical liver disease commonly have serious nutritional problems both generally and also relating to specific macronutrients, fat-soluble vitamins and clotting factors [94]. Many patients with CF have increased losses of bile salts in the intestine [52]. Bile salt deficiency compromises lipolysis leading to a reduction in fat absorption of up to 50%. In one study lipolysis of the substrate was not affected in patients with CF related liver disease using the ^{13}C-mixed triacylglycerol breath test [95], but, bile salt concentration or intestinal loss was not studied. Ursodeoxycholic acid (URSO) is accepted as a treatment for biochemical liver disease and has a beneficial effect on liver enzyme levels. Whether treatment with URSO leads to an improvement in nutritional state is unknown. Studies that show long-term effects on the prevention of fibrosis are lacking, and the observation that the nutritional state of patients with CF and liver disease improved with URSO [96] was not confirmed in a controlled trial [97]. Liver transplantation in such patients, however, has a beneficial effect on their nutritional state [98].

4.5. Diabetes mellitus

Estimates of prevalence of CF related diabetes mellitus (CFRD) vary from 2.5% to 12% of patients, increasing considerably with age. In Denmark, 32% of patients with CF developed diabetes mellitus by the age of 25 years [99]. This obviously has considerable nutritional significance. CF related diabetes mellitus shares features of both type 1 and type 2 diabetes but is a distinct clinical entity. The primary cause is insulin deficiency but it is also influenced by unique CF conditions. Undernutrition, chronic and acute infection, elevated energy expenditure, glucagon deficiency, malabsorption, abnormal intestinal transit time, bacterial overgrowth, and liver dysfunction all influence glucose tolerance.

The diagnostic criteria of (CFRD) are reported in a recent consensus report of the US CF Foundation [100]:

(i) 2-h plasma glucose (PG) >11 mmol/l during a 75-g OGTT; (ii) fasting PG (FPG) >7.0 mmol/l on two or more occasions; (iii) FPG >7.0 mmol/l plus casual glucose level >11.1 mmol/l regardless time or last meal; and (iv) casual glucose levels >11.1 mmol/l on two or more occasions with symptoms. The HbA1c screening should not be used for detection of new cases of CF related diabetes mellitus but only for monitoring the degree of control of blood glucose levels in patients with established CFRD. The management of CFRD is beyond the scope of the present consensus on nutrition.

5. Essential fatty acid (EFA) deficiency

Patients with CF carry a high risk of low essential fatty acid levels, which have often been considered as essential fatty acid deficiency. Plasma and tissue lipids of patients with CF tend to have low contents of the precursor EFA, linoleic and α-linolenic acids [101,102]. Several studies have also reported reduced levels of omega-3 long-chain polyunsaturated fatty acids (LC-PUFA), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [103]. In contrast, controversial data exist for omega-6 LC-PUFA, such as arachidonic acid (AA), which may be normal, reduced or even increased [103]. A disturbed EFA and LC-PUFA status has been related to a variety of physiological impairments and adverse effects, such as altered membrane and cellular functions, skin lesions, alteration of immune, renal, hepatic and pulmonary functions [104,105]. Many of these symptoms are also observed in animals with experimental EFA deficiency [106]. However, the question of possible causality in patients with CF requires further clarification.

Proposed mechanisms that can lead to polyunsaturated fatty acid depletion in patients with CF include maldigestion and malabsorption of dietary lipids, as well as underweight and negative energy balance with an increased beta-oxidation of polyunsaturated fatty acids. Moreover, enhanced peroxidative destruction of polyunsaturated fatty acids in patients with poor antioxidant status and high oxidative stress induced by infections may contribute to low polyunsaturated fatty acid concentrations. Alterations of EFA conversion to LC-PUFA which were proposed to be either causally linked to the basic defect in CF or secondary to disease related physiological alterations, an increased turnover of linoleic acid [107] and an increased release of arachidonic acid (AA) from phospholipids [108] have been proposed but require further clarification. It is also of interest that in a controlled trial, URSO therapy for 6 months led to an improvement of the EFA status [109].

6. Vitamin deficiency

6.1. Vitamin A

Low serum vitamin A concentrations are frequent in untreated patients with CF, regardless of age, nutritional status, meconium ileus, Shwachman score, genotype and exocrine pancreatic function [110]. Pancreatic enzyme replacement to correct steatorrhoea apparently fails to normalise serum vitamin A concentrations. The occurrence of biochemical deficiency in patients without steatorrhoea, suggests that other mechanisms, such as a disturbance in mobilisation of hepatic stores, are involved. A positive correlation between retinol binding protein (RBP) concentrations and zinc status has been demonstrated [111]. Studies currently available trying to clarify the interrelationship between vitamin A status and liver disease are inconclusive. In a recent study hepatic vitamin A stores in CF were found to be lower than normal, they decreased with age and showed no correlation to the severity of CF related liver disease [112].

Many studies of vitamin A in CF underline the poor correlation between biochemical and clinical findings. However, patients with CF with decreased serum retinol concentrations were found to have disturbed dark adaptation, which was reversed by supplementing vitamin A [113]. Morphological changes of the eye like xerosis, have been reported recently but are exceptional [114]. Low vitamin A levels are associated with poorer clinical status [115] and impaired lung function [116]. Whether this is related to the role of vitamin A in the immune system or any other specific function is unclear. Plasma levels of β-carotene that acts as an antioxidant on its own are low in practically all pancreatic insufficient patients with CF.

6.2. Vitamin D

A quarter of infants with CF detected in a newborn screening program were shown to have decreased serum concentrations of 25-OH-cholecalciferol in the first 3 months of life, before any treatment was started [117]. This finding could be explained by the low serum levels of the vitamin D-binding protein in CF homozygotes, suggesting that in CF hypovitaminosis D is mainly a transport problem [118]. Sunlight is the major determinant of the amount of vitamin D in the body, which mainly depends on seasonal variation, geographical location and skin pigmentation. When there is sufficient skin exposure to ultraviolet light, dietary supplementation is not essential. As result it is very difficult to establish normal serum values and the frequency of deficiency in different studies varies accordingly [119]. For vitamin D decreased biochemical concentrations have also been found much more frequently than clinical

deficiency states such as rickets. In adolescents and adults osteopenia and osteoporosis are well documented but decreased vitamin D concentrations only play a minor part [119,120].

There are anecdotal reports of severe clinical deficiency states in heavily pigmented adolescents living in northern regions, after darker winter months.

6.3. Vitamin E

α-Tocopherol is a powerful antioxidant protecting lipoproteins and cellular membranes against destruction. Oxidative stress is enhanced in patients with CF due to chronic respiratory inflammation [121]. Almost all newly diagnosed patients with CF have low vitamin E plasma concentrations irrespective of exocrine pancreatic function [110]. This and the fact that administration of pancreatic enzymes does not correct an existing biochemical vitamin E deficiency suggests that exocrine pancreatic insufficiency is not the only underlying pathogenetic mechanism. Impaired intestinal availability of bile acids plays an equal or even more important role in vitamin E uptake from the gut [122,123]. CF related liver disease with only mild cholestasis does not seem to play a significant role in this context [124]. Vitamin E absorption is also improved by URSO [124]

Although biochemical vitamin E deficiency is a frequent finding in patients with CF, clinical symptoms are a rare event. However, long-standing severe biochemical deficiency will eventually result in irreversible neurological damage. Therefore, routine testing for biochemical vitamin E deficiency is recommended. A consequence of biochemical vitamin E deficiency is an impairment of the resistance of plasma lipids to oxidation [125]. In infants with CF, clinical deficiency mainly presents as haemolytic anaemia while in older patients symptoms are related to the nervous system [126,127]. In one study abnormal brainstem evoked auditory potentials were detected and proposed as useful in the evaluation [128]. No abnormalities, however, were detected in nerve conduction [129]. Whether vitamin E supplementation protects against oxidative lung damage in patients with CF is still speculative. A positive correlation between percent FEV_1 and plasma vitamin E levels in patients with CF was recently reported [130].

6.4. Vitamin K

As long as vitamin K was only supposed to be important in coagulation, a diagnosis of deficiency was exceptional and supplements were restricted to patients with haemoptysis, uncontrollable malabsorption from pancreatic disease, liver disease, intestinal resections or long-term use of antibiotics [131]. Recent studies indicate vitamin K acts as a cofactor in the carboxylation, not only of prothrombin involved in coagulation, but

also of osteocalcin in bone formation [132]. Determination of proteins induced in vitamin K absence (PIV-KA), a new sensitive method for the measurement of this vitamin, demonstrates that deficiency is common in CF especially in unsupplemented pancreatic insufficiency [133]. Based on the carboxylation state of these proteins in patients with CF, 5 mg vitamin K was supplemented weekly without reaching normal levels in these patients [134]. But in a recent study from Toronto unsuspected biochemical vitamin K deficiency was partly corrected by an oral supplement [135]. A water-soluble, oral vitamin K preparation is often given to patients with CF, even though adequate comparative data on the bioavailability of vitamin K from the standard preparation and the water-soluble micellar preparation are unavailable. The parenteral route should only be chosen to correct an acute symptomatic deficiency, in severe liver disease or malabsorption. Further studies are needed in patients with CF with liver disease, severe malabsorption, small bowel resections and long-term antibiotic use before the optimal dose of vitamin K is determined.

6.5. Water soluble vitamins

Water-soluble vitamins usually do not pose an appreciable problem in CF. Many patients with CF with exocrine pancreatic insufficiency have a disturbed Schilling test indicating an abnormal vitamin B12 absorption, but pancreatic enzyme preparations promote absorption of vitamin B12. Patients who underwent extensive resections of the terminal ileum need lifelong treatment with a parenteral administration of 100 μg vitamin B12 per month. In contrast, vitamin B12 deficiency in pancreatic sufficient patients with CF not taking pancreatic enzyme supplements is exceptional [136]. Plasma vitamin C concentrations are inversely related to age and different indices of inflammation [137]. The antioxidant role of vitamin C is currently under investigation.

7. Mineral and trace element deficiency

In the daily diet, macronutrients are needed for the body in relative large amounts and are important for the cell or the extracellular compartment. Micronutrients as cofactors are essential for enzymatic reactions or as structural elements of proteins.

7.1. Minerals

Sodium and chloride are the most important ions in the extracellular fluid [138]. The mean daily intake of sodium is between 6 and 9 g a day for adults, which is in excess of the daily minimal requirement (<3.5 g/ day). Newborns need more sodium and chloride in relation to their bodyweight for the increase of extra

Table 2
Minimal daily requirements for sodium, chloride and potassium in normal individuals

Age	Sodium (mg)	Chloride (mg)	Potassium (mg)
<1 year	120–200	180–300	500–700
>1 year	225–500	350–750	1000–2000

Source: National Research Council, 1989. In CF more loss through sweat and stool can be anticipated, and has to be supplemented on an individual basis.

cellular volume. The minimal need is based on the concentration of breast milk (sodium 160 mg/l, chloride 385 mg/l, and potassium 500 mg/l). In the first 6 months the population reference intake (PRI) for sodium is 23 mg/kg per day, the recommended intake is 23–46 mg/kg per day. For newborn babies the acceptable intake for chloride is 35–71 mg/kg per day. The daily sodium loss in sweat is approximately 500 mg in adults. The loss may increase 10 times in CF during exercise in the sun, sometimes accompanied by hyponatraemia and alkalosis. In moderate climates the excess of sodium intake in food compensates this extra loss. The serum sodium concentration is regulated by the renin-angiotensin-aldosterone axis that diminishes the sodium excretion in the urine during activation. In most patients this balance is maintained. Since human milk is low in sodium, breast fed babies may need supplementation during fever or hot summer months.

Potassium is the most important intracellular cation, involved in nerve conductance, muscle contraction and blood pressure. Potassium loss with sweat is low. The mean potassium intake for adults is between 2 and 3.5 g daily. Rapidly growing young children need during increased growth velocity approximately 78 mg/100 kcal (recommended intake) or 35–78 mg/kg per day (acceptable intake) (Table 2).

Calcium is important for the mineralisation of the skeleton, muscle contractions and signal transmission in the nervous system [139]. Fat malabsorption and vitamin D deficiency are the main causes of low calcium uptake in the intestine [140]. Calcium intake in non-CF individuals is dependent on age and growth velocity. Children need 400 to 800 mg calcium and adolescents 800–1200 mg calcium daily. In CF, tetany, rickets or clotting abnormalities are rare. Plasma calcium levels and calcium excretion in the urine are normal. In young children with CF bone mineralisation is thought to be normal, but in adolescent and adult patients with CF bone mineral density and bone content is often diminished and spontaneous fractures are described [141]. Also phosphate homeostasis is strongly related to calcium and regulated by vitamin D [142]. Most food products are rich in phosphate and a deficient intake is exceptionally rare. Only young infants with low body weight

are at risk for nutritional deficiency of phosphate. The ideal ratio of calcium to phosphate intake is 2:1.

Only 1% of the body store of magnesium (adult: 25 g) is in the extracellular fluid. Magnesium is important in the skeleton (60% of the magnesium pool) and muscles and in many biochemical processes. Normal serum levels are 0.7–1.0 mmol/l. Based on the concentration in human milk the recommended dose for infants and young children is 7 mg/kg per day and for adults 3.5 mg/kg per day. Hypomagnesaemia is characterised by tremor, tetany, neuromuscular irritability and seizures. Magnesium absorption is disturbed in pancreatic insufficiency and is closely associated with calcium and phosphorus. Urinary magnesium excretion is increased by aminoglycosides probably causing renal tubular damage [143]. Serum levels do not always correlate with the severity of symptoms.

7.2. Trace elements

The iron store in the body is 3–4 g of which 70% is in the red blood cells and 25% in ferritin and haemosiderin in liver, spleen and bone marrow. The transport protein in plasma is transferrin. Children need 5–10 mg of iron daily. Iron deficiency is frequent in CF and caused by multiple factors: inadequate dietary intake, malabsorption, chronic infection, and blood loss. Pancreatic enzymes may be responsible for impaired oral iron absorption and iron should not be supplemented in close proximity to pancreatic enzyme supplements [144]. It is unclear whether iron supplementation will improve the iron status, which is monitored by measuring serum ferritin levels in patients with CF. Ferritin levels can be increased during infection.

The total body zinc content is 2 g and most of it is intracellularly deposited in the skeleton, muscles, liver and skin. Red blood cells contain 0.9–1.5 mg zinc per 100 ml. Zinc has an important function in many enzymes. Deficiency is characterised by growth retardation, acrodermatitis, and disturbed immune function. Children need 5–10 mg/day and adults up to 15 mg. It is suspected that subclinical zinc deficiency due to fat malabsorption is wide spread in CF and is caused by zinc forming complexes with fat and phosphorus [145]. Pancreatic enzyme supplements improve zinc absorption [146].

Like zinc, copper is part of many enzymes and found mostly intracellularly in liver, muscle and bone. In the plasma copper is bound by caeruloplasmin. Copper deficiency results in anaemia, neutropenia, heart disorders, muscle weakness, immune disorders, pancreatic atrophy, and connective tissue impairment. Copper deficiency is only partially represented by plasma copper levels because caeruloplasmin is an acute phase protein. There is insufficient information to support supplemen-

tation of copper more than the age appropriate recommended daily allowance (RDA) [147].

Selenium is an essential part of the antioxidant glutathione peroxidase. Deficiency of selenium causes cardiomyopathy and muscle weakness. Glutathione peroxidase activity in red blood cells is a better indicator of selenium status than plasma values. In CF there is an indication that the selenium status is disturbed [148], however, at present, it cannot be recommended to supplement selenium in patients with CF. Pancreatic enzyme preparations contain 0.5–1.6 μg/g of selenium and this amount is sufficient to affect glutathione peroxidase activity [149].

Iodine is incorporated in hormones of the thyroid gland. Iodine deficiency does not occur in CF, since iodine is easily absorbed from food. Iodine requirements increase with age: 40 μg during the first 6 months to 150 μg at 10 years. Manganese is necessary for the antioxidant superoxide dismutase. The total body pool is 10–20 mg and supplementation for patients with CF is not needed. Similarly, molybdenum deficiency is extremely rare and does not need supplementation. Chromium plays a role in carbohydrate and lipid metabolism and protein synthesis and is important for growth. Patients with CF had normal plasma levels during supplementation of 0.5–0.75 μg/kg per day [150]. It is questionable if supplementation is necessary. Fluorine is found in tooth and bone and supplements are not required.

8. Antioxidant deficiency

In patients with CF, the antioxidant protective screen is markedly disturbed as a result of impaired status of glutathione, vitamin E and carotenoids such as β-carotene and lycopene. Occasionally low plasma concentrations of albumin, vitamin C and selenium are found. Glutathione deficiency has been described to occur both locally in the CF airways and systemically [151]. Glutathione is transported via the CFTR, suggesting that glutathione deficiency is intrinsically related to CF [152]. The glutathione status is also associated with nutritional status [153]. Carotenoids are highly lipophilic compounds not considered to be vitamins, of which the plasma and lipoprotein concentrations are very low in CF patients with exocrine pancreatic insufficiency. In addition to its provitamin A function, β-carotene acts as an antioxidant. Correction of poor vitamin E and β-carotene status to normal enhances the resistance against oxidation of plasma lipoproteins [125,154], decreases plasma lipid peroxidation [154–156] and reduces inflammation [157]. For counterbalancing the enhanced reactive oxygen species production due to chronic inflammation, full correction of the antioxidant screen is warranted. Future studies should address the question as to whether the final goal of antioxidant supplementation is to achieve plasma concentrations in CF higher than those in healthy subjects.

9. Prevention of malnutrition and treatment of pancreatic insufficiency

Prevention of malnutrition requires early intervention. Therefore early diagnosis is of importance and may be achieved by neonatal screening [9]. Following diagnosis, frequent reviews by a specialist CF dietician are mandatory; during the first 12 months after diagnosis at least once every month, thereafter at least every 3 months. The frequency of clinical reviews depends on the clinical state, control of the malabsorption and weight gain. Patients on a special diet (e.g. vegetarian) should be monitored more closely.

The majority of individuals with CF can tolerate a normal to high fat diet if treated with pancreatic enzymes in doses (Tables 3 and 4) matched to fat intake [158]. A 3-day faecal fat study and dietary assessment is the best measure of fat absorption. The diet is quite often low in fibre but for some who experience recurrent abdominal pain, an increase in fibre intake to 30 g per day with additional water may reduce abdominal symptoms [159] and may lead to an improved appetite and energy intake in some patients. In children with CF and well-controlled absorption and only mild chest infections, a normal energy intake may be sufficient. However, if the nutritional state and/or growth are abnormal, the diet should provide in excess of 20% of the recommended daily amount and high-energy dietary supplements or even enteral tube feeding may be required. As energy requirements vary so widely it is important that an assessment of each individual's needs is undertaken.

9.1. Infant feeding

Infants with CF fed on breast milk [5] achieve normal weight gain and growth by the age of 1 year as do infants on normal formulae [6] and those fed on a predigested medium chain triglyceride containing formula [160]. For the first year of life the ESPGHAN recommendation of exclusive breast feeding for the first 4–6 months of life is appropriate for the infant with CF. [5]. If breast-feeding is not possible or there is insufficient milk, cows' milk-based infant formulae can be used [6,160]. Whole cows' milk should not be given during the first year of life. Infants who receive a feed containing adequate energy and who are also given an appropriate dose of supplemental pancreatic enzymes should thrive satisfactorily irrespective of the type of milk [6,161]. Extensively hydrolysed protein formulae should be considered for infants who have undergone extensive gut resection for meconium ileus and for those with milk intolerance (e.g. cows' milk allergy or lactose intolerance) [162]. A feed containing medium chain

Table 3
Minimum enzyme content of pancreatic enzyme preparations

Name	Maker	Lipase	Protease	Amylase
Enteric-coated microspheres				
Cotazym	Thiemann			
10 000		10 000 Ph Eur u	375 Ph Eur u	6250 Ph Eur u
20 000		20 000 Ph Eur u	750 Ph Eur u	12 500 Ph Eur u
30 000		30 000 Ph Eur u	1125 Ph Eur u	18 750 Ph Eur u
40 000		40 000 Ph Eur u	1500 Ph Eur u	25 000 Ph Eur u
Nutrizym[a] GR	Merck	10 000 BP u	650 BP u	10 000 BP u
Pancrease	Janssen-Cilag	5000 BP u	330 BP u	2900 BP u
Enteric-coated minimicrospheres				
Creon	Solvay			
10 000		10 000 Ph Eur u	600 Ph Eur u	8000 Ph Eur u
25 000		25 000 Ph Eur u	1000 Ph Eur u	18 000 Ph Eur u
40 000		40 000 Ph Eur u	2000 Ph Eur u	30 000 Ph Eur u
For children		5000 Ph Eur u	200 Ph Eur u	3600 Ph Eur u
Enteric-coated minitablets				
Nutrizym[a]	Merck			
10		10 000 BP u	500 BP u	9000 BP u
22		22 000 BP u	1100 BP u	19 800 BP u
Panzytrat[a]	Knoll			
10 000		10 000 Ph Eur u	500 Ph Eur u	9000 Ph Eur u
25 000		25 000 Ph Eur u	1250 Ph Eur u	22 500 Ph Eur u
Pancrease HL[a]	Janssen-Cilag	25 000 BP u	1250 BP u	22 500 BP u

Note: For amylase and lipase 1 BP unit=1 Ph Eur unit; for protease there is no direct equivalence between BP and Ph Eur units because of the use of different assay methods.

[a] Eudragit-coated.

triglycerides should be considered in patients with cholestasis or uncontrolled steatorrhoea. If weight gain is poor, additional energy supplements may be added to formulae or a high-energy infant formula used. A normal to high fat weaning diet is recommended depending on the infant's growth. The first 2 years are a period of very rapid growth; therefore close monitoring of the general condition, the nutritional state and the growth rate of the infant with CF is needed. If poor weight gain is related to an increase in frequency of chest infections, vigorous treatment of the latter will both improve the nutritional state and reduce the amount of pulmonary damage.

Treatment of acute and chronic lung infection normally results in an increase in bodyweight, which is related to a reduction in systemic inflammation [163–166].

9.2. Control of malabsorption achieved with current enzymes preparations

Enzyme preparations may differ in their enzyme content, which often varies with batches, in their dissolution characteristics in relation to the pH and to other constituents of the duodenal fluid [167] and in the size of the particles and their rate of exit from the stomach in relation to the meal. The practical details of administration, including adjusting the enzyme dose to the fat intake and the timing in relation to the meal will have a significant effect. Future studies are needed in this context.

Coefficients of fat absorption of between 85% and 95% of intake should be possible with presently available enzyme preparations [168–173]. Nevertheless, a substantial number of patients with CF do not achieve normal absorption [174]. Based on reports of fibrosing colonopathy, various guidelines for the use of pancreatic enzymes in CF have appeared [58,175–177]. Recommendations are summarised in Table 4.

9.3. Failure to control gastrointestinal symptoms

Sometimes, control of symptoms is not achieved even with a dose of enzyme equivalent to the recommended 10 000 IU lipase/kg per day [175] is given in an appropriate manner. The degree of residual malabsorption should be estimated and other gastrointestinal disorders should be considered. A progressive increase in enzyme dose without further investigations is not recommended [178]. Distal intestinal obstruction syndrome (DIOS) is characterised by recurrent attacks of abdominal pain with variable symptoms of obstruction and is relatively common in patients with CF [179]. An increase in pancreatic enzyme dose in patients with DIOS is likely to worsen the abdominal pain and constipation [22]. Other possible gastrointestinal problems include gastro-oesophageal reflux, which seems to be common both in infants [180,181] and older patients

Table 4
Recommendations for pancreatic enzyme supplementation therapy in CF

Infants

•	Use a microsphere or minimicrosphere preparation
•	For every 120 ml infant formula or breast milk give as the initial dose of one-quarter to one-third of a capsule of standard strength pancreatin (as Creon 10 000 = 2500–3333 IU lipase; as Pancrease = 1666–2500 IU lipase). These doses equate to approximately 400–800 IU lipase per g of dietary fat.
•	Mix the enzyme microspheres or minimicrospheres with a small amount of infant formula or expressed breast milk or fruit puree and give from a spoon directly before the feed.
•	Increase the dose gradually according to clinical symptoms, appearance of the stools and objective assessment of weight gain, growth and absorption.
•	Once solid food is introduced, individually titrate enzyme dose according to the fat intake. Regular advice from a dietician is mandatory for best results.
•	Aim to keep the lipase intake below 10 000 IU per kg body weight per day.

Older children and adults

•	Initial dose of 1–2 capsules of standard pancreatin preparation (as Creon 10 000 = 10 000-20 000 IU lipase; as Pancrease = 5000–10 000 IU lipase) per meal and a half to one capsule with fat containing snacks.
•	One paediatric unit has continued to use high strength microsphere capsules (Creon 25 000) without problems.
•	Enzymes should be given with all fat containing foods and supplements. The dose should be worked out individually, initially with the help of a dietician, and varied according to the fat intake. Dose requirements can vary widely between 500 and 4000 IU lipase per gram of dietary fat.
•	The capsules should be swallowed whole at as early an age as possible and many children will manage this by 3 or 4 years, some very much earlier. If removed from the capsules, the microspheres should *not* be sprinkled on or mixed with the whole meal but should be mixed with a little fluid or food and immediately given from a spoon in one swallow. They should not be crushed or chewed.
•	Enzymes are best given at the beginning or early in the meal, e.g. half the dose at the beginning and half in the middle of the meal.
•	The dose is gradually increased until the symptoms are controlled when evidence is sought that absorption has been controlled.
•	Patients and parents should be encouraged to discuss any problems they may have with adherence to enzyme treatment.
•	In tube or gastrostomy fed patients pancreatic enzymes should be given before and after the feed.

From*: Littlewood JM, Wolfe SP. Control of malabsorption in cystic fibrosis. Paediatr Drugs 2000;2:205–222.

[182], inflammatory bowel disease [183], pancreatitis in pancreatic sufficient patients [184], short bowel with bacterial overgrowth and adhesions after intestinal surgery, liver and gall bladder disease [185], cows' milk protein allergy or lactose maldigestion [162] and even intolerance to the porcine enzyme preparations [186].

Patient adherence to treatment provides another problem in the control of gastrointestinal symptoms and the role of an experienced dietician to discuss the practical details of treatment in such circumstances cannot be over emphasised.

Reduction of gastric acid has improved absorption in patients with CF where control was poor even with enteric-coated acid resistant enzymes. Treatments have included cimetidine [187]; ranitidine [188] omeprazole [189] and lansoprazole [190] Long-term side effects of this group of drugs have not been investigated. Taurine-conjugated bile acids are in relatively short supply due to the gastrointestinal losses, which occur in CF. There

is a relatively greater compensatory production of glycine-conjugated bile acids [52]. Therefore, in CF taurine-conjugated bile acids, which are more efficient at lipid solubilisation, are deficient in plasma and bile [53]. There is still controversy as to whether or not oral taurine corrects the deficiency and improves the malabsorption. Further studies are needed [191].

10. Side effects of pancreatic enzymes

Hyperuricaemia and hyperuricosuria, which occurred with the older less pure pancreatic extracts, are no longer a problem with the modern microsphere preparations [192]. Soreness of the mouth may occur with powdered preparations or if acid resistant microspheres are chewed or held in the mouth and dissolve with a pH of greater than 5.5. If older powdered preparations are used in breast-fed infants, soreness both of the infant's mouth and of the mother's nipples may occur.

Perianal irritation may result from the passage of significant enzyme activity in the stools if intestinal transit is rapid or the enzyme dose excessive. The porcine origin of the pancreatic enzymes causes apparently insignificant immunological response in most patients [193], however, this has been suggested a possible aetiological factor in fibrosing colonopathy (FC) [194]. Severe acute and chronic gastrointestinal allergic reactions [186] and general allergic reactions may occur in people administering powdered enzymes to infants with CF [195,196]. In patients who have had chronic significant fat malabsorption a too rapid increase in enzyme dose may cause severe constipation.

Fibrosing colonopathy (FC) was first reported in 1994 [197,198]. The exact pathophysiology is still uncertain, however, the progressive increase in pancreatin dose prescribed for persisting intestinal symptoms appears to have been a major factor in reaching the very high doses implicated in FC [198,199]. Toxicity from the co-polymer Eudragit L30 D55, an acrylic resin based on polymethacrylic acid and polyacrylic acid esters, used as an enteric coating by some pancreatin preparations, has also been proposed [198,200,201]. However, acrylic resin is widely used in many different preparations and toxicity the role in the causation of FC is not generally accepted [202–204]. A list of co-polymer coated preparations is given in Table 3, together with phthalate-coated alternatives.

With the increased awareness of FC, pancreatin dosing has become more conservative with the recommendation not exceeding 10 000 USP lipase/kg per day; this and restriction of high strength preparations ($>25 000$ IU lipase/capsule) to adult populations has resulted in a dramatic fall in the incidence of FC in Europe.

11. EFA treatment

Dietary treatment of patients with CF should aim at avoiding clearly subnormal levels of EFA and LC-PUFA. Strategies to achieve that goal include an adequate supply of energy, polyunsaturated fatty acids of both the n-6 and the n-3 series in balanced proportions, as well as antioxidants. Several studies have failed to demonstrate any general improvement by supplementation of EFA [205,206] but physiological improvement in liver steatosis, kidney function and sodium transport have been reported [207,208]. However, excessive intakes of EFA and LC-PUFA carry the risk of adverse effects, such as enhanced lipid peroxidation and unbalanced synthesis of specific eicosanoids, with clinical consequences.

Beneficial effects of supplying increased intakes of specific fatty acids, or groups of fatty acids, have been proposed. High supplies of fish oil rich in the omega-3 fatty acid EPA reduce the liberation of proinflammatory leukotrienes from granulocytes of patients with CF in vitro [209] and in vivo [210] and were reported to improve pulmonary function in some preliminary studies [211,212], this observation deserves further evaluation. Very high intakes of the omega-3 fatty acid DHA have been reported to reduce organ damage in a mouse model of CF. Whether or not comparable clinical benefits can be achieved in patients with CF supplemented with high doses of DHA should be evaluated. Based on the available evidence it is recommended that patients with CF should receive an adequate dietary intake of omega-3 fatty acids as is recommended for the general population, it is considered premature to recommend high pharmacological doses of specific omega-3 fatty acids prior to further characterisation of the efficacy of such intervention. In a controlled trial, URSO therapy for 6 months led to an improvement in EFA status [109].

12. Vitamin supplementation

Clinical evidence of vitamin deficiency is rare and there is no uniformity on the goals of supplementation. Relevant questions are how to prevent isolated biochemical deficiencies and subclinical abnormalities. The present consensus favours prophylactic substitution of those vitamins for which low blood levels or deficiencies have ever been described. The initial dose proposed usually is adequate to normalise blood concentrations in most patients with CF without causing hypervitaminosis. It is prudent to measure vitamin blood levels after a few months and after any change in the treatment of the malabsorption because this can influence vitamin absorption. Subsequent supplementation should be adjusted according to the patient's blood levels; afterwards annual monitoring is sufficient [117].

12.1. Vitamin A

The vitamin A intake should be high enough to achieve serum concentrations in the normal range without provoking side effects. This can be achieved with daily doses between 4000 and 10 000 IU of a fat-soluble preparation [114]. Water-soluble or water-miscible forms of vitamin A preparations have not been studied in CF. As absorption and metabolism of vitamin A differ between individuals, serum concentrations should be estimated at least once a year and 3–6 months after any change in dose. If plasma levels are low despite supplementation to the above levels consideration should be given to patient compliance and the RBP and the zinc level should be checked. In view of the potential toxicity of vitamin A, supplementation should never exceed 20 000 IU if the RBP is low. Special consideration must be given to vitamin A supplementation during pregnancy. A relationship has been suggested between the incidence of birth defects and high vitamin A intake

($>10\,000$ IU/day). In CF serum levels should be checked at the start of pregnancy. If plasma levels are high it is recommended the dose is reduced. If levels are low or normal supplementation should continue at a level less than $10\,000$ IU/day.

12.2. B-Carotene

In patients with CF with pancreatic insufficiency a daily dose of 0.5–1 mg/kg β-carotene corrected very low plasma and lipoprotein concentrations to normal [156–158]. However, plasma concentrations need to be monitored to make sure that above normal concentrations will not be achieved in the individual patient, given the fact that in smokers, a group of subjects also exhibiting oxidative stress, higher than normal plasma β-carotene concentrations were associated with serious side effects.

12.3. Vitamin D

As sunlight is the major source of vitamin D for the body, serum concentrations will depend largely on endogenous production in the skin and this will differ between individuals [213].

Decreased serum concentrations of 25-OH-CC have been described in patients with CF receiving daily oral supplementation of up to 2000 IU of vitamin D [214]. No cases of hypervitaminosis D were reported with this concentration in patients with CF. No studies are available on the effect of intermittent large doses. To keep blood levels within a normal range, a daily dose of between 400 and 2000 IU is required. Recent evidence suggests that the serum level should be maintained within the upper part of the normal range to ensure optimal bone health [214]. In severe hepatocellular disease 25-hydroxylation is impaired and therefore 25-OH-vitamin D is preferred for supplementation [214].

12.4. Vitamin E

Clinical deficiency states are exceptional in patients with CF [130], but enhanced susceptibility to lipid peroxidation has been demonstrated to occur in patients with low vitamin E status [126]. Therefore regular vitamin E supplementation is recommended. As vitamin E is non-toxic there is no objection to using up to 400 IU daily ($=400$ mg all-rac-α-tocopheryl acetate $=450$ mg dl-α-tocopheryl acetate or 268 mg RRR-α-tocopherol) [124]. In animals and humans side effects were only seen when excessively high amounts were given. The more expensive water-soluble form has no advantage over the fat-soluble form, provided the latter is taken with pancreatic enzymes [124,215]. RRR-α-tocopherol and all-rac-α-tocopheryl acetate were shown to be equally effective, when given at a dose of 400 mg

IU/day [124]. With that dose a normal resistance to oxidation of lipoprotein could be achieved [126]. It has been recommended to use for the interpretation of adequate levels of the plasma, tocopherol/total lipid or cholesterol ratio as an index of vitamin E status particularly when levels are low, because the vitamin E levels rise with lipids.

12.5. Vitamin K

Routine supplementation with vitamin K has always been controversial. But recent studies have revealed unsuspected biochemical deficiency, which may be an important factor in the osteoporosis in CF [134]. Patients with demonstrated or suspected deficiency should be given 10 mg daily. However, the dose required to correct PIVKA levels is still controversial. A recent randomised prospective study found better biochemical parameters with a supplementation of 5 mg weekly [134]. Even then normal levels were not achieved in all patients [135]. Probably better results are achieved with a daily supplement [136]. For systemic substitution, an oral water-soluble form should be given; parenteral administration should be reserved for correction of acute symptomatic deficiency, in severe hepatocellular disease or uncorrectable malabsorption.

12.6. Water-soluble vitamins

Patients who underwent extensive resections of the terminal ileum need lifelong treatment with parenteral administration of 100 μg vitamin B_{12} per month. A supplement of at least 100 mg vitamin C per day should be prescribed for patients with an unbalanced diet, deficient in vitamin C. No other water-soluble vitamin supplements are needed.

12.7. Conclusion

The doses proposed in Table 5 are those reported to achieve normal plasma concentrations in patients with CF without liver disease that will not cause toxicity. The availability of a preparation that combines the vitamins at the required doses could help improve compliance and make life of patients with CF more convenient. Fat-soluble vitamins need to be taken at the same time as a meal for which pancreatic enzymes are required.

13. Mineral and trace element supplementation

13.1. Minerals

Sodium and chloride supplementation is usually not necessary except during exercise in hot climates when extra salt is recommended (for minimal need see Table

Table 5
Recommendations for vitamin supplements in CF

Fat soluble vitamins	CF patients needing supplements	Starting dose
A	EPI	4000–10 000 IU[a]/day
D	EPI, northern countries	400–800 IU[b]/day depending on serum level
E	All	100–400 IU[c]/day
K	EPI, cholestasis	1 mg/day to 10 mg/week
B12	Schilling test <45% after ileal resection	100 μ i.m./month
Other water soluble vitamins	None if dietary intake is normal	

EPI, exocrine pancreatic insufficiency. Conversion factors: IU to mg: [a]vitamin A: $IU \times 0.3 = \mu$; [b]vitamin D: $IU/40 = \mu$; [c]vitamin E: all-rac-α-tocopheryl acetate: $IU = mg$; RRR-α-tocopherol: $IU/1.49 = mg$.

The need for vitamin supplementation in pancreatic sufficient patients should be assessed on an individual basis according to plasma levels.

2). Moreover, breast fed infants are not always able to meet their sodium chloride needs and may require supplementation, particularly when exposed to high ambient temperatures or at high water losses due to fever, sweating or tachypnoea. Children and adults with CF need oral calcium supplementation if their diet is found to be deficient.

During long-term treatment with aminoglycosides and severe malabsorption patients with CF may need extra substitution of magnesium.

13.2. Trace elements

The need for iron supplementation should be determined by the plasma transferrin saturation and not given simultaneously with pancreatic enzymes. In growth retardation and severe steatorrhoea zinc should be supplemented. Selenium supplements may be needed in special areas (e.g. in Switzerland, Austria). However, these should be used with caution, as there is a narrow range between supplementary and toxic doses.

14. Supplementation with antioxidants

Vitamin E is the most important fat-soluble antioxidant and the doses recommended for supplementation are presented above. However, higher doses will be required if the intake of polyunsaturated fatty acids (such as DHA) is increased above the average dietary intake. Supplementation with vitamin C and selenium, which represents an integral constituent of the antioxidant enzyme glutathione peroxidase, and glutathione precursors or derivatives need to prove to be beneficial but randomised controlled studies are required before their use can be recommended.

15. Refeeding the malnourished child

In many CF studies a relationship has been shown between body weight and lung function [216], but it is unclear what is cause and what is effect [217]. Reasons for a decrease in energy intake include anorexia, feeding disorders (neonatal tube feeding), depression, interactions with parents, oesophagitis, DIOS, iatrogenic fat restriction, decreased appetite by concomitant drugs or pulmonary inflammation and lack of general well being. In most cases early intervention is extremely important to prevent negative long-term effects. Intervention is often complicated because the multifactorial nature of the problem.

Interventions include behavioural treatment, psychological support, dietetic advice, oral supplementation, nasogastric tube feeding, gastrostomy feeding and parenteral feeding. Although there are reports that eating is a problem for patients with CF [218], a positive effect of any form of nutritional intervention with oral supplements is still unproven [219,220] possibly due to small and uncontrolled studies which differ in design, parameters and outcome measures. It is important to start interventions early [217] (Table 1).

15.1. Recommendations

15.1.1. Oral feeding

0–1 year: Breast feeding is the preferred way of feeding infants and also should be recommended for those with CF. Mothers of breast-fed infants may need to be encouraged to feed more frequently to increase milk formation and thus meet their infant's energy needs. Some breast fed infants may benefit from sodium chloride supplementation, particularly at high ambient temperatures or with increased water losses due to fever, diarrhoea, tachypnoea or increased sweating.

Formula fed infants will usually receive regular formula that can be supplemented with up to a total carbohydrate content of 10–12 g/100 ml and a total fat content of 5 g/100 ml which will achieve an energy density of approximately 1 kcal/ml. Supplementation should be gradually increased up to these levels. A special dietetic product for infants with a high energy

content could also be used but may be less flexible and more expensive. The volume of feed should be adapted to achieve normal weight gain and growth velocity, which often means that higher volumes will need to be fed than in healthy babies. Solids should be introduced at the normal age of 4–6 months. Most infants with CF will thrive satisfactorily on a normal weaning diet. If the infant is failing to thrive, higher fat foods may be used, with appropriate adjustment of the pancreatic enzymes.

2–5 years: A normal to high fat diet should be advised depending on growth and nutritional status. In the past oral supplements were often unpalatable, however, recent studies show that some supplements are well accepted by this age group. A compromise must be found between palatability, volume and the optimal composition to obtain maximal compliance. For children in this age range specific commercially products are available now.

5 years: Standard adult supplements can be used and the choice is often directed by the taste of the patient and long-term acceptance. Preferably, high energy density formulae should be used.

15.1.2. Supplements

There are many types of nutritional supplements available. Palatability, volume and the optimal composition determine the choice. For children of approximately 1–5 years age specific commercially available products can be used. Standard adult supplements are suitable for children over 5 years. The choice of the supplement is often determined by the taste preference of the patient to obtain maximal compliance. High-energy dense preparations should be used wherever possible.

Supplements should be given before or after meals or before bedtime to ensure that the appetite for normal food is maintained. At the present time there is a lack of evidence to support the use of dietary supplements [219]. A large multicentre trial is currently addressing this issue in the UK.

15.1.3. Tube feeding

Tube feeding can be administered by naso-gastric tube or by gastrostomy, patient's preference determining the choice of the route. Preferably, tube feeding should be given overnight with the aim to maintain normal dietary intake during the day. Gastro-oesophageal reflux (GER) may be a problem in some patients and should be monitored closely before feeding is recommended. If GER is documented, a Nissen's fundoplication may be indicated prior to gastrostomy insertion. In patients with borderline glucose intolerance nocturnal hyperglycaemia should be monitored and if necessary treated with insulin. Normally, a high calorie non-elemental formula can be used. If this is not tolerated, and in rare instances,

individual patients may benefit from elemental or medium chain triglyceride (MCT) containing formulae. Because of the slow flow of fat infusion absorption is generally adequately controlled by taking a small dose of enzymes at the start and during the feed. If patients awake spontaneously they can also take extra enzymes during night.

15.1.4. Total parenteral nutrition

Total parenteral nutrition is not recommended for long-term treatment, but may be useful for short term support in infants and children after major (GI) surgery and in the severely ill patient waiting for a lung or liver transplant. Several studies have shown an improvement in nutritional status with supplementary parenteral feeding [221,222].

16. Treatment of the malnourished adult

The goal of treating the malnourished adult is to increase lean body mass [21]. Initially a high fat and high calorie diet may be used, but oral supplements are often needed. Oral supplements should be highly palatable and provide a large amount of calories in a small volume, preferably by having a high content of fat. The main disadvantage of oral supplements is their influence on normal appetite, thereby adversely affecting the energy intake. However, the use of palatable high calorie oral supplements showed an overall increase in daily energy intake. If dietary interventions, including oral supplementation, fail to increase bodyweight, one should consider nasogastric tube or gastrostomy feeding (PEG). Percutaneous sonographic gastrostomy (PSG) can be performed under local anaesthesia by an experienced radiologist guided by ultrasound [223] or by a gastroenterologist using fluoroscopic guidance. Enteral feeding offers the possibility of feeding overnight, thereby not influencing the patients' appetite during the day [224,225]. The formula used for tube feeding may be non-elemental provided that enzymes are taken at the start and preferably during the nocturnal feeding [226] (see Section 15.1). Parenteral nutrition is generally not recommended since it is limited by volume, immobilises the patient and increases the risk of sepsis [227]. For these reasons the use of parenteral nutrition is usually restricted to when the GI tract is non-functional or in severely malnourished patients awaiting transplantation.

When hyperalimentation is given as the sole intervention in malnourished adult patients with CF, body weight will increase but lean body mass may remain unchanged [228]. Since increase of muscle mass is an important target, the combination of nutritional support with specific muscle stimulation appears a relevant option. Combining nutritional support with an exercise programme may result in an increase in lean body mass, maximal

ventilatory capacity, oxygen uptake and maximal exercise capacity [229–231].

17. The important questions and answers

Q1. Does a nutritional deficit exist in CF patients and, if so, what impact does it have on disease progression and survival?

A1. Many patients with CF present with below normal weight and/or height. Even with treatment, malnutrition may occur leading to reduced weight gain and growth and nutritional deficiencies, which are associated with a more rapid progression, the disease and shortened survival. Nutritional deficits may be responsible for the delay in the onset of puberty and menarche in teenagers with CF. The nutritional state of patients has steadily improved over the years and is likely to be one of the major factors contributing to the increased survival in recent years. Provided the chest infection and associated inflammation are treated effectively, prevention and early treatment of nutritional deficits are associated with improved growth and respiratory function and are likely to improve prognosis.

Q2. How does malnutrition present in CF and how do we measure it?

A2. Malnutrition may present as underweight, subnormal longitudinal growth, or deficiencies in one or more single nutrients. Underweight is defined as a weight for height of less than 90% using appropriate normal values for the population or in adults, body mass index of less than 18.5 kg/m^2. In children, BMI values should be interpreted on the basis of gender-specific centile charts or *Z* scores. Standard deviation scores give similar information and are more convenient for statistical calculations. In the absence of normal values the longitudinal assessment of nutrition and growth is particularly important. Knowledge of the puberty state is necessary for the adequate assessment of growth over the age of 10 years. Assessment of diet, clinical and laboratory indicators of nutritional status should be performed at least annually. A longitudinal assessment is important.

Q3. What are the causes of malnutrition in CF?

A3. Malnutrition in CF has several causes including intestinal malabsorption, inadequate intake and increased energy requirements. Maldigestion and malabsorption, particularly of fat and protein, are early and severe in most patients. The most important cause is pancreatic insufficiency with inadequate secretion of enzymes and bicarbonate; other factors include impaired mucosal uptake, altered motility, liver disease and bile salt abnormalities and structural abnormalities due to previous bowel surgery. Energy intake may be inadequate due to poor appetite secondary to chronic pulmonary and gastrointestinal disease, acute infection or psychosocial problems causing abnormal eating behaviour. Energy

requirements are increased due to chronic infection and inflammation, the excessive work of breathing and possibly secondary to the primary genetic defect.

Q4. Are essential fatty acids reduced in plasma and tissues of CF patients, and which mechanisms are responsible?

A4. Many CF patients have low plasma and tissue contents of linoleic acid and of omega-3 long-chain polyunsaturated fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid. Omega-6 long-chain polyunsaturated fatty acids such as arachidonic acid are more variable. These changes have been related to a variety of physiological impairments and adverse effects and are considered as essential fatty acid deficiency. Possible mechanisms that lead to polyunsaturated fatty acid depletion include fat malabsorption, underweight and negative energy balance with an increased beta-oxidation of polyunsaturated fatty acids, and enhanced peroxidative destruction of polyunsaturated fatty acids due to poor antioxidant status and high oxidative stress. Moreover, the conversion of essential fatty acids to long-chain polyunsaturated fatty acids may be altered, and linoleic acid turnover and arachidonic acid release from phospholipids may be increased.

Q5. Is there evidence for vitamin deficiency?

A5. Blood levels of fat-soluble vitamins are frequently low in patients with CF. Biochemical evidence of vitamin A, vitamin D, vitamin E and vitamin K deficiency is frequently found even in the absence of clinical symptoms. Deficiencies of water-soluble vitamins are rare.

Q6. Is there evidence for mineral and trace element deficiency?

A6. Patients with CF are at risk of salt depletion and metabolic alkalosis in particular during fever, hot weather and exercise. They may suffer from mineral and trace element deficiency, including chloride, sodium, calcium, magnesium, zinc, iron and selenium.

Q7. What is the strategy to prevent malnutrition?

A7. Early diagnosis of CF by neonatal screening and early recognition of CF specific complications and non-CF related disorders, followed by appropriate treatments in specialised CF centres including optimal treatment of pulmonary infection, is recommended. There should be frequent and regular surveillance of the patients including expert dietary advice. For dietary intake in the first year of life the ESPGAN recommendations should be followed including exclusive breast-feeding in the first 4–6 months of life but if necessary a normal infant formula can be used. If the child fails to thrive, early intervention is mandatory. If children are gaining weight normally on a normal diet this can be continued. No fat limitations and no advice to increase fibre intake should be given. At all ages there should be close attention to behavioural factors, which may compromise adherence to medical treatment and food intake. Patients on special

diets (e.g. vegetarians) should be monitored particularly closely.

Q8. Does aggressive treatment of pulmonary disease in CF influence nutritional state?

A8. Malnutrition, infection, inflammation and disturbed immune function create a vicious cycle in which each factor in turn may exacerbate the other. Effective treatment of lung infection has been demonstrated to improve the nutritional status.

Q9. Does treatment of the nutritional status influence lung disease?

A9. Nutritional interventions have been shown to inhibit the decrease in lung function, thereby improving survival in patients with CF.

Q10. How do we treat pancreatic insufficiency?

A10. All patients with CF who have evidence of malabsorption due to pancreatic insufficiency should be treated with pancreatic enzymes using standard preparations. Special attention has to be paid to other conditions if fat malabsorption, poor growth or underweight persist in spite of adequate dosing. Recommendations are summarised in Tables 3 and 4.

Q11. What is the significance of fibrosing colonopathy (FC)?

A11. Although the exact pathophysiology of FC is still unknown, the progressive increase in enzyme dose in response to persisting symptoms was a major factor in reaching the very high doses implicated in the cause of fibrosing colonopathy. Enzyme doses in excess of 10 000 IU lipase/kg per day should only be used with caution and after excluding other causes of malabsorption and persisting gastrointestinal symptoms.

Q12. Is there an influence of ursodeoxycholic acid (URSO) on nutritional status in CF patients with CF related liver disease?

A12. URSO may enhance biliary bicarbonate secretion and bile flow. Some studies have provided indications for positive effects of URSO on biochemical parameters indicating liver disease, the bioavailability of dietary lipids and lipid soluble vitamins, and on weight gain which deserve further evaluation.

Q13. Is there a role for treatment strategies targeting essential fatty acid status in CF patients?

A13. Dietary treatment of CF patients should aim at avoiding subnormal levels of essential fatty acids and long-chain polyunsaturated fatty acids. Energy, antioxidants and polyunsaturated fatty acids of both the omega-6 and the omega-3 series should be adequately supplied in balanced proportions. Fish oil preparations have an anti-inflammatory effect. Their effect on pulmonary function deserves further evaluation. Similarly, beneficial effects of high amounts of DHA in CF mice need to be substantiated in CF patients. CF patients should consume omega-3 fatty acids in amounts as recommended for the general population.

Q14. What vitamins need to be supplemented, in which doses and how?

A14. In general fat-soluble vitamins should be given to patients with CF. Recommended doses are given in Table 5. Vitamins should be given with a fat containing meal and pancreatic enzymes. The dose of the vitamins should be sufficient to achieve and maintain normal blood concentrations. While there is little risk of overdosing with vitamins E and K, caution is necessary for vitamins A and D.

Q15. What minerals and trace elements need to be substituted?

A15. During exercise, in hot environments and during fever, sodium and chloride supplementation is recommended. During long-term treatment with aminoglycosides patients with CF may need additional magnesium. Iron and zinc deficiency should be corrected and results controlled biochemically.

Q16. How should we re-feed the malnourished child?

A16. In case of malnutrition or weight loss there should be a full re-evaluation of all the possible causes that may affect the nutritional state. If nutritional intervention is indicated, guidelines can be used. The first approach should be to ensure maximal energy intake using normal or energy-dense foods. Recommendations are given in the table. Supplements should be given between or after meals or before bedtime to ensure that the appetite for normal food is maintained. Tube feeding can be administered by naso-gastric tube or by gastrostomy, patients' preference determining the choice of the route. Preferably, tube feeding should be given overnight with the aim to maintain normal dietary intake. Total parenteral nutrition is only recommended for special indications.

Q17. How do we re-feed the malnourished adult?

A17. The indication for supplemental feeding either by oral supplements or tube feeding is the same in adults as in older children and adolescents. Monitoring for impaired glucose tolerance is needed. Psychosocial issues including body image should be addressed. An exercise-training program with the aim to increase lean body weight should accompany re-feeding in adolescents and adults.

Q18. Should anabolic steroids be used in re-feeding the malnourished CF patient?

A18. In a very limited number of CF patients it has been shown that megestrol acetate, a progestagon, may temporarily lead to an increased appetite, an increase in body weight with an increase in lean body mass and pulmonary function. Disadvantages are the possible development of diabetes, inhibition of growth, adrenal suppression, cardiomyopathy and behavioural problems including depression. Because of the side effects and the limited data available, anabolic medication should not be used in routine clinical practice.

Q19. Which future studies should be carried out to find more evidence for optimal nutrition in CF?

1. Long-term studies concerning the effect of antioxidants, particularly studies involving vitamin E, C, β-carotene and selenium, on clinical progress, respiratory function and nutritional status.
2. Long-term supplementation studies measuring vitamin K status and bone mineral density. The relationship between antibiotic therapy, gut flora and vitamin K status should be studied. In general drug-nutrient interactions should be determined and studied.
3. Quality vs. quantity in nutritional support.
4. Eating disorders and behaviour—categorisation, prevention, treatment and intervention studies.
5. Factors affecting adherence to enzyme therapy.
6. Reasons for failure to correct levels of nutrients.
7. Optimal levels of various nutrients for people with CF.
8. Evaluation of appetite stimulants.
9. Value of new prokinetic drugs.
10. Benefit of specific anti-inflammatory treatment, e.g. anti-TNF.
11. Role of leptins in cystic fibrosis.
12. Value of high-energy oral supplements.
13. Ideal feeds for enteral feeding.
14. Best enzyme regimen for overnight feeds.
15. Possibility of delaying pancreatic insufficiency.
16. Role of acid suppression in improving steatorrhoea.
17. Optimal prevention and management of osteoporosis.
18. Confirmation and study of reduced head circumference brain development and fatty acid status during infancy.
19. Early intervention in the development of diabetes mellitus. At what stage do we intervene?
20. Use of anabolic steroids.
21. Treatment with DHA or fish oil.
22. Role of probiotics in nutrition and infection.
23. Effect on nutritional status of continuous antimicrobial treatment, started soon after diagnosis following neonatal screening.
24. Optimisation of oral supplements.
25. Further knowledge of the homeostasis of calcium, the lipid peroxidation and role of selenium and zinc deficiency in young children.
26. The potential effects of URSO on nutritional status, in subgroups of patients with CF who have different disease states and conditions.
27. The effects of supplying increased intakes of specific fatty acids, and of groups of fatty acids such as long-chain omega-3 fatty acids, should be evaluated.
28. Relationship of fatty acids and immune functions and neurological development.

References

[1] Lewis PA. The epidemiology of cystic fibrosis. In: Hodson ME, Geddes D, editors. 2nd ed. Cystic fibrosis. London: Arnold; 2000.

[2] Santis G. Basic molecular biology. In: Hodson ME, Geddes D, editors. 2nd ed. Cystic fibrosis. London: Arnold; 2000.

[3] Sheppard MN. The pathology of cystic fibrosis. In: Hodson ME, Geddes D, editors. 2nd ed. Cystic fibrosis. London: Arnold; 2000.

[4] Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56:746–50.

[5] Mearns MB. Growth and development. In: Hodson ME, Norman AP, Batten JC, editors. Cystic fibrosis. London: Bailliere Tindall; 1983. p. 183–96.

[6] Holliday KE, Allen JR, Waters DL, Gruca MA, Thompson SM, Gaskin KJ. Growth of human milk-fed and formula-fed infants with cystic fibrosis. J Pediatr 1991;118:77–9.

[7] Simmonds EJ, Wall CR, Wolfe SP, Littlewood JM. A review of infant feeding practices at a regional cystic fibrosis unit. J Hum Nutr Diet 1994;7:31–8.

[8] Ghosal S, Taylor CJ, Pickering M, et al. Disproportionate head growth retardation in cystic fibrosis. Arch Dis Child 1995;72:150–2.

[9] Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001;107:1–13.

[10] Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583–91.

[11] Karlberg J, Kjellmer I, Kristianssson B. Linear growth in children with cystic fibrosis. Acta Paediatr Scand 1991;80:508–14.

[12] Waters DL, Wilcken B, Irwig L, et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child 1999;80:F1–F7.

[13] Cystic Fibrosis Foundation. Patient Registry 1998 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 1999.

[14] Hui-Chuan L, Kosorok MR, Sondel SA, et al. Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. J Pediatr 1998;132:478–85.

[15] Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25–9.

[16] Morison S, Dodge JA, Cole TJ, et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997;77:497–500.

[17] Littlewood JM, Wolfe SP. Growth, development and nutrition. In: Hodson ME, Geddes DM, editors. 2nd ed. Cystic fibrosis. London: Arnold; 2000.

[18] Weltman EA, Stern RC, Doershuk CF, Moir RN, Palmer K, Jaffe AC. Weight and menstrual function in patients with eating disorders and cystic fibrosis. Pediatrics 1990;85:282–7.

[19] Johannesson M, Gottlieb C, Hjelte L. Delayed puberty in girls with cystic fibrosis despite good clinical status. Pediatrics 1997;99:29–34.

[20] Byard PJ. The adolescent growth spurt in cystic fibrosis. Ann Hum Biol 1994;21:229–40.

[21] Ramsey BW, Farrell PM, Pencharz P. Nutritional assessment and management in cystic fibrosis: a consensus report. The Consensus Committee. Am J Clin Nutr 1992;55:108–16.

[22] Littlewood JM. Gastrointestinal complications of cystic fibrosis. J R Soc Med 1992;85(Suppl 19):13–9.

[23] Poustie VJ, Watling RM, Ashby D, Smyth RL. Reliability of percentage ideal weight for height. Arch Dis Child 2000;88:183–4.

[24] Buckler JMH. A Reference Manual of Growth and Development. 2nd ed. Oxford: Blackwell Science, 1997.

[25] Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity and the stages of puberty. Arch Dis Child 1976;51:1170–9.

[26] Freeman JV, Cole TJ, Chinn S, Jones PRM, White EM, Preece MA. Cross-sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17–24.

[27] Van't Hof MA, Haschke F. Euro-Growth references for body mass index and weight for length. J Pediatr Gastroenterol Nutr 2000;31(Suppl 1):S48–S59 (and the Euro-growth study group).

[28] Shin J, Corey M, Kalnins D, Pencharz P. A comparison of anthropomorphic standards for evaluation of CF patients. Pediatr Pulmonol 1997;14(Suppl):312.

[29] International Obesity Task Force. Obesity; preventing and managing the global epidemic. Report of the WHO consultation on obesity, Geneva, 3–5th June 1998. Geneva: WHO, 1998.

[30] Cole TJ, Belizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J 2000;320:1240–3.

[31] Johnston JL, Leong MS, Checkland EG, Zuberbuhler PC, Conger PR. Body fat assessed from body density and estimated from skinfold thickness in normal children and children with cystic fibrosis. Am J Clin Nutr 1988;48:1362–6.

[32] Newby MJ, Kiem NL, Brown DL. Body composition of adult cystic fibrosis patients and control subjects as determined by densitometry, bioelectrical impedance, total electrical body conductivity, skinfold measurements and deuterium oxide dilution. Am J Clin Nutr 1990;52:209–13.

[33] Shepherd RW, Holt TL, Greer R, Cleghorn GJ, Thomas BJ. Total body potassium in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;9:200–5.

[34] Greer R, Shepherd R, Cleghorn G, Bowling FG, Holt T. Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;13:52–8.

[35] Azcue M, Fried M, Pencharz PB. Use of bioelectrical impedance analysis to measure total body water in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1993;16:440–5.

[36] Slosman DO, Casez JP, Pichard C, et al. Assessment of whole body composition with dual-energy X-ray absorptiometry. Radiology 1992;185:593–8.

[37] Henderson RC, Madsen CD. Bone mineral density in children and adults with cystic fibrosis. J Pediatr 1996;128:28–34.

[38] Haworth CS, Selby PL, Webb AK, et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999;54:961–7.

[39] Littlewood JM. Abdominal pain in cystic fibrosis. J R Soc Med 1995;88(Suppl. 25):9–17.

[40] Mullins PE, Liechti-Gallati S, Di Silvio L, Brook CG, Paes-Alves AF. Short stature in a patient with cystic fibrosis caused by a 6.7-kb human growth hormone deletion. Horm Res 1991;36:4–8.

[41] Shaw NJ, Fraser NC, Weller PH. Asthma treatment and growth. Arch Dis Child 1997;77:284–6.

[42] Littlewood JM. Value of comprehensive assessment and investigation in the management of cystic fibrosis. In: Escobar H, Basquero L, Suarez L, editors. Clinical ecology of cystic fibrosis.Elsevier; 1993. p. 181–7.

[43] Kennedy JD, Dinwiddie R, Daman-Williams C, Dillon MJ, Matthew DJ. Pseudo Bartter's syndrome in cystic fibrosis. Arch Dis Child 1990;65:786–7.

[44] Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992;120:533–40.

[45] Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992;50:1178–84.

[46] Couper R, Corey M, Durie PR, et al. Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic sufficient patients with cystic fibrosis. J Pediatr 1995;127:408–13.

[47] Balasubramanian K, Zenther-Munro P, Batten JC, et al. Increased intragastric acid-resistant activity and lipolysis in pancreatic steatorrhoea due to cystic fibrosis. Pancreas 1992;7:305–10.

[48] Hoffman R, Isenberg JN, Powell GK. Carbohydrate malabsorption is normal in school age cystic fibrosis children. Dig Dis Sci 1987;32:1071–4.

[49] Zentler-Munro PL. Pancreatic exocrine insufficiency and cystic fibrosis. Curr Opin Gastroenterol 1989;5:706–10.

[50] Robinson PJ, Smith AL, Sly PD. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig Dis Sci 1990;35:1299–304.

[51] Zentler-Munro PL, Fitzpatrick JWF, Batten JC, et al. Effect of intraduodenal acidity on aqueous phase bile acid and lipid concentrations in pancreatic steatorrhoea due to cystic fibrosis. Gut 1984;25:500–7.

[52] Walters MP, Littlewood JM. Faecal bile acid and dietary residue excretion in cystic fibrosis: age group variations. J Pediatr Gastroenterol Nutr 1998;27:296–300.

[53] Roy CC, Weber AM, Morin CL, et al. Abnormal biliary composition in cystic fibrosis. Effect of pancreatic enzymes. N Engl J Med 1977;292:1301–5.

[54] Sinaasappel M. Relationship between intestinal function and chloride secretion in patients with cystic fibrosis. Netherlands J Med 1992;41:110–4.

[55] Kalivianakis M, Minich DM, Bijleveld CMA, et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long chain fatty acids. Am J Clin Nutr 1999;69:127–34.

[56] Dalzell AM, Freestone NS, Billington D, et al. Small intestinal permeability and oro-caecal transit time in cystic fibrosis. Arch Dis Child 1990;65:585–8.

[57] Oppenheimer EH, Esterly JR. Pathology of cystic fibrosis. Review of the literature and comparison with 146 autopsied cases. Perspect Pediatr Pathol 1975;2:241–78.

[58] Borowitz DS, Grand RJ, Durie PR. Fibrosing colonopathy in patients with cystic fibrosis. J Pediatr 1995;127:681–4.

[59] Gilbert J, Kelleher J, Walters MP, Littlewood JM. Markers for faecal fat estimation in monitoring steatorrhoea in cystic fibrosis. Gut 1988;29:1286–8.

[60] Bekers O, Postma C, Lombarts AJ. Determination of faecal fat by near-infrared spectroscopy. Eur J Clin Chem Clin Biochem 1995;33:83–6.

[61] Van de Kamer JH, ten Bokkel Huinink H, Weyers HA. Rapid method for the determination of fat in faeces. J Biol Chem 1949;177:347–55.

[62] Walters MP, Kelleher J, Gilbert J, Littlewood JM. Clinical monitoring of steatorrhoea in cystic fibrosis. Arch Dis Child 1990;63:99–102.

[63] Van der Neucker A, Pestel A, Tran TM, et al. Clinical use of acid steatocrit. Acta Paediatr 1997;86:466–9.

[64] Brown GA, Sule D, Williams J, et al. Faecal chymotrypsin: a reliable index of exocrine pancreatic function. Arch Dis Child 1988;63:785–9.

[65] Soldan W, Henker J, Sprossig C. Sensitivity and specificity of quantitative determination of pancreatic elastase 1 in feces of children. J Pediatr Gastroenterol Nutr 1997;24:53–5.

[66] Cade A, Walters MP, McGinley N, et al. Evaluation of fecal elastase-1 as a measure of pancreatic exocrine function in children with cystic fibrosis. Pediatr Pulmonol 2000;29:172–6.

[67] Amarri S, Harding M, Coward WA, et al. 13 carbon mixed triglyceride breath test and pancreatic supplementation in cystic fibrosis. Arch Dis Child 1997;76:349–51.

[68] Kalivianakis M, Elstrodt J, Havinga R, et al. Validation in an animal model of the carbon 13-labeled mixed triglyceride breath test for the detection of intestinal fat malabsorption. J Pediatr 1999;135:444–50.

[69] Brown RC, Chalmers DM, Rowe VL, Kelleher J, Littlewood JM, Losowsky MS. Comparison of the diagnostic value of serum pancreatic isoamylase and immunoreactive trypsin measurement in patients with cystic fibrosis. J Clin Pathol 1982;35:547–9.

[70] Reilly JJ, Evans TJ, Wilkinson J, Paton JY. Adequacy of clinical formulae for estimation of energy requirements in children with cystic fibrosis. Arch Dis Child 1999;81:120–4.

[71] Thomson MA, Bucolo S, Quirk P, Shepherd RW. Measured versus predicted resting energy expenditure in infants: a need for reappraisal. J Pediatr 1995;126:21–7.

[72] Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Thorax 1996;51:126–31.

[73] Burdet L, Hugli O, Aubert JD, Schutz Y, Roulet M, Fitting JW. Effect of elective antibiotic therapy on resting energy expenditure and inflammation in cystic fibrosis. Eur J Pediatr 1999;158:711–6.

[74] Stallings VA, Fung EB, Hofley PM, Scanlin TF. Acute pulmonary exacerbation is not associated with increased energy expenditure in children with cystic fibrosis. J Pediatr 1998;132:493–9.

[75] Steinkamp G, Drommer A, von der H. Resting energy expenditure before and after treatment for Pseudomonas aeruginosa infection in patients with cystic fibrosis. Am J Clin Nutr 1993;57:685–689.

[76] Bell SC, Bowerman AM, Nixon LE, Macdonald IA, Elborn JS, Shale DJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest 2000;30:553–9.

[77] Wilmott RW, Frenzke M, Kociela V, Peng L. Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis. Pediatr Pulmonol 1994;18:21–7.

[78] Amin N, Dozor AJ. Effects of administration of aerosolized recombinant human deoxyribonuclease on resting energy expenditure in patients with cystic fibrosis. Pediatr Pulmonol 1994;18:150–4.

[79] McCloskey M, Redmond AO, Pyper S, et al. Total energy expenditure in stable patients with cystic fibrosis. Clin Nutr 2001;20:235–41.

[80] O'Rawe A, McIntosh I, Dodge JA, et al. Increased energy expenditure in cystic fibrosis is associated with specific mutations. Clin Sci 1992;82:71–6.

[81] Zemel BS, Kawchak DA, Cnaan A, Zhao H, Scanlin TF, Stallings VA. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis. Pediatr Res 1996;40:578–86.

[82] Thomson MA, Wilmott RW, Wainwright C, Masters B, Francis PJ, Shepherd RW. Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. J Pediatr 1996;129:367–73.

[83] Fried MD, Durie PR, Tsui LC, Corey M, Levison H, Pencharz PB. The cystic fibrosis gene and resting energy expenditure. J Pediatr 1991;119:913–6.

[84] Tomezsko JL, Stallings VA, Kawchak DA, Goin JE, Diamond G, Scanlin TF. Energy expenditure and genotype of children with cystic fibrosis. Pediatr Res 1994;35:451–60.

[85] Vaisman N, Levy LD, Pencharz PB, et al. Effect of salbutamol on resting energy expenditure in patients with cystic fibrosis. J Pediatr 1987;111:137–9.

[86] Morrison JM, O'Rawe A, McCracken KJ, Redmond AOB, Dodge JA. Energy intakes and losses in cystic fibrosis. J Hum Nutr Diet 1994;7:39–46.

[87] Collins CE, O'Loughlin EV, Henry R. Discrepancies between males and females with cystic fibrosis in dietary intake and pancreatic enzyme use. J Pediatr Gastroenterol Nutr 1998;26:258–62.

[88] Nasr SZ, Hurwitz ME, Brown RW, Elghoroury M, Rosen D. Treatment of anorexia and weight loss with megestrol acetate in patients with cystic fibrosis. Pediatr Pulmonol 2000;29:244.

[89] Marcand V, Baker SS, Stark TJ, Baker RD. Randomized, double blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. J Pediatr Gastroenter Nutr 2000;31:264–9.

[90] Eubanks V, Atchinson J, Arani R, et al. Effects of megestrol acetate on energy intake, weight gain, body composition, and resting energy expenditure in cystic fibrosis patients. Pediatr Pulmonol 2000;20(Suppl):A518.

[91] Hardin DS, Ellis KJ, Dyson M, et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. J Pediatr 2001;139(5):636–42.

[92] Colombo C, Crosignani A, Battezzati M. Liver involvement in cystic fibrosis. J Hepatol 1999;31:946–54.

[93] Linblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999;30:1151–8.

[94] Sokol RJ, Durie PR. J Pediatr Gastroenterol Nutr 1999;28:S1–S13 (for the Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group).

[95] Ling SC, Amarri S, Slater C, Hollman AS, Preston T, Weaver LT. Liver disease does not affect lipolysis as measured with the ^{13}C-mixed triacylglycerol breath test in children with cystic fibrosis. J Pediatric Gastroenterol Nutr 2000;30:368–72.

[96] Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and long-standing cholestasis. Gut 1990;31:918–21.

[97] Merli M, Bertasi S, Servi R, et al. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo controlled, crossover trial. J Pediatr Gastroenterol Nutr 1994;19:198–203.

[98] Noble-Jamieson G, Barnes N, Jamieson N, Friend P, Calne R. Liver transplantation for hepatic cirrhosis in cystic fibrosis. J R Soc Med 1996;89(Suppl 27):31–7.

[99] Lanng S, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in cystic fibrosis. Arch Dis Child 1991;66:612–6.

[100] Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus. A consensus conference report. Diabetes Res Clin Pract 1999;45:61–73.

[101] Strandvik B, Bröbbegard M, Gilljam H, Carlstedt-Duke J. Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis. Scand J Gastroenterol Suppl 1988;143:1–4.

[102] Strandvik B. Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis. Acta Paediatr Scand Suppl 1989;363:58–65.

[103] Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr 2001;139:650–5.

[104] Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr −/− mice. Proc Natl Acad Sci USA 1999;96:13995–4000.

[105] Steinkamp G, Demmelmair H, Ruhl-Bagheri I, von der Hardt H, Koletzko B. Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2000;31:418–23.

[106] Korotkova M, Strandvik B. Essential fatty acid deficiency affects the fatty acid composition of the rat small intestinal and colonic mucosa differently. Biochim Biophys Acta 2000;1487:319–25.

[107] Roulet M, Franscarolo P, Rappaz I, Pilet M. Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997;156:952–6.

[108] Carlstedt-Duke J, Bronnegard M, Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basis defect. Proc Natl Acad Sci USA 1986;83(23):9202–6.

[109] Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 1997;130:52–8.

[110] Lancellotti L, D'Orazio C, Mastella G, Mazzi G, Lippi U. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur J Pediatr 1996;155:281–5.

[111] Navarro J, Desquilbet N. Depressed vitamin A and Retinol binding protein in cystic fibrosis. Effects of zinc supplementation. Am J Clin Nutr 1998;34:1439–40.

[112] Lindblad A, Diczfalusy U, Hultcrantz R, Thorell A, Strandvik B. Vitamin A concentration in the liver decreases with age in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1997;24:264–70.

[113] Huet F, Semama D, Maingueneau C, Charavel A, Nivelon JL. Vitamin A deficiency and nocturnal vision in teenagers with cystic fibrosis. Eur J Pediatr 1997;156:949–51.

[114] Brooks HL, Driebe WT, Schemmer GG. Xerophthalmia and cystic fibrosis. Arch Ophthalmol 1990;108:354–7.

[115] Raybner RJ, Tyrrell JC, Hiller EJ, et al. Night blindness and conjunctival xerosis caused by vitamin A deficiency in patients with cystic fibrosis. Arch Dis Child 1989;641:151–6.

[116] Carr SB, Dinwiddie R. Annual review or continuous assessment? J R Soc Med 1996;89(Suppl 27):3–7.

[117] Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis. J Pediatr 1999;135:601–10.

[118] Coppenhaver D, Kneppers F, Schidlow D, et al. Serum concentrations of vitamin D-binding protein (group-specific component) in cystic fibrosis. Hum Genet 1981;57:399–403.

[119] Henderson RC, Madsen CD. Bone mineral content and body composition in children and young adults with cystic fibrosis. Pediatr Pulmonol 1999;27:80–4.

[120] Donovan DS, Papadopoulos A, Staron RB, et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 1998;157:1892–9.

[121] Brown RK, Wyatt H, Price JF, Kelly FJ. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J 1996;9:334–9.

[122] Winklhofer-Roob BM, Shmerling DH, Schimek MG, Tuchschmid PE. Short-term changes in erythrocyte α-tocopherol content of vitamin E-deficient patients with cystic fibrosis. Am J Clin Nutr 1992;55:100–3.

[123] Skopnik H, Kusenbach G, Bergt U, et al. Taurine supplementation in cystic fibrosis (CF): effect on vitamin E absorption kinetics. Klin Pediatr 1991;203:28–32.

[124] Thomas PS, Bellamie M, Geddes D. Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid. Lancet 1995;346:1230–1.

[125] Winklhofer-Roob BM, Ziouzenkova O, Puhl H, et al. Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. Free Radic Biol Med 1995;19:725–33.

[126] Swann IL, Kendra JR. Anemia, vitamin E deficiency and failure to thrive in an infant. Clin Lab Haematol 1998;20:61–3.

[127] Bye AME, Muller DPR, Wilson J, Wright VM, Mearns MB. Symptomatic vitamin E deficiency in cystic fibrosis. Arch Dis Child 1985;60:163–4.

[128] Vaisman N, Tabachnik E, Shahar E, Gilai A. Impaired brain-stem auditory evoked potentials in patients with cystic fibrosis. Dev Med Child Neurol 1996;38:59–64.

[129] De Schepper J, Hachimi Idrissi S, Dab I, Schmedding E. Nerve conduction in vitamin E deficient cystic fibrosis patients. Eur J Pediatr 1997;156:251–2.

[130] De Vriese S, Robberecht E, De Gussem J, Christophe A. FEV$_1$ correlates with plasma vitamin E in young cystic fibrosis (CF) patients: an argument for early administration? Netherlands J Med 54:S61,A144.

[131] Durie PR. Vitamin K and the management of patients with cystic fibrosis. Can Med Assoc J 1994;151:933–6.

[132] Weber P. Management of osteoporosis: is there a role for vitamin K? Int J Vitam Nutr Res 1997;67:350–6.

[133] Rashid M, Durie P, Andrew M, et al. Prevalance of vitamin K deficiency in cystic fibrosis. Acta Pediatr 1999;70:378–82.

[134] Beker LT, Ahrens RA, Fink RJ, et al. Effect of vitamin K$_1$ supplementation on vitamin K status in cystic fibrosis patients. J Pediatr Gastroenterol Nutr 1997;24:512–7.

[135] Wilson DS, Ahrens RA, Fink RJ, et al. Treatment of vitamin K deficiency in cystic fibrosis: effectiveness of a daily fat-soluble vitamin combination. J Pediatr 2001;138:851–5.

[136] Gueant JL, Champigneulle B, Gaucher P, Nicolas JP. Malabsorption of vitamin B12 in pancreatic insufficiency of the adult and of the child. Pancreas 1990;5:559–67.

[137] Winklhofer-Roob BM, Ellemunter H, Fruhwirth M, et al. Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of association with lung inflammation. Am J Clin Nutr 1997;65:1858–66.

[138] Legris GJ, Dearborn D, Stern RC, et al. Sodium space and intravascular volume: dietary sodium effects in Cystic Fibrosis and healthy adolescent subjects. Pediatrics 1998;101:48–56.

[139] Laursen EM, Mølgaard C, Michaelsen KF, Koch C, Müller J. Bone mineral status in 134 patients with cystic fibrosis. Arch Dis Child 1999;81:235–40.

[140] Salamoni F, Roulet M, Gudinchet F, Pilet M, Thiebaud D, Burckhardt D. Bone mineral content in cystic fibrosis patients: correlation with fat-free mass. Arch Dis Child 1996;74:314–8.

[141] Haworth CS, Webb AK, Egan JJ, et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000;118:434–9.

[142] Aris RM, Lester GE, Dingman S, Ontjes DA. Altered calcium homeostatis in adults with cystic fibrosis. Osteoporos Int 1999;10:102–8.

[143] Akbar A, Rees JH, Nyamugunduru G, English MW, Spencer DA, Weller PH. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis. Acta Paediatr 1999;7:783–5.

[144] Zempsky WT, Rosenstein BJ, Carroll JA, Oski FA. Effect of pancreatic enzyme supplements in iron absorption. Am J Dis Child 1989;143(8):969–72.

[145] Krebs NF, Sontag M, Accurso FJ, Hambidge KM. Low plasma zinc concentrations in young infants with cystic fibrosis. J Pediatr 1998;12:761–4.

[146] Easley D, Krebs N, Jefferson M, et al. Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. J Pediatr Gastroenterol Nutr 1998;26:136–9.

[147] Percival SS, Bowser E, Wagner M. Reduced copper enzyme activities in blood cells of children with cystic fibrosis. Am J Clin Nutr 1995;62:633–8.

[148] Portal BC, Richard MJ, Faure HS, Hadjian AJ, Favier AE. Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 1995;61:843–7.

[149] Winklhofer-Roob BM, Tiran B, Tuchschmid PE, van 't Hof MA, Shmerling DH. Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis. Free Radic Biol Med 1998;25:242–9.

[150] Bougle D, Bureau F, Voirin J, Neuville D, Drosdowsky M, Duhamel JF. Plasma chromium concentrations in normal infants and cystic fibrosis patients. Biol Trace Element Res 1992;32:53–5.

[151] Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993;75:2419–24.

[152] Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol 1998;275:C323–C326.

[153] Lands LC, Grey V, Smountas AA, Kramer VG, McKenna D. Lymphocyte glutathione levels in children with cystic fibrosis. Chest 1999;116:201–5.

[154] Winklhofer-Roob BM, Puhl H, Khoschsorur G, van 't Hof MA, Esterbauer H, Shmerling DH. Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during β-carotene supplementation in cystic fibrosis. Free Radic Biol Med 1995;18:849–59.

[155] Lepage G, Champagne J, Ronco N, et al. Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis. Am J Clin Nutr 1996;65:87–93.

[156] Rust P, Eichler I, Renner S, Elmadfa I. Effects of long-term oral β-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. Int J Vitam Nutr Res 1998;68:83–7.

[157] Winklhofer-Roob BM, Schlegel-Haueter SE, Khoschsorur G, van 't Hof MA, Suter S, Shmerling DH. Neutrophil elastase/α 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral β-carotene supplementation. Pediatr Res 1996;40:130–4.

[158] Collins CE, O'Loughlin EV, Henry RL. Fat gram target to achieve high energy intake in cystic fibrosis. J Pediatr Child Health 1997;31:142–7.

[159] Gavin J, Ellis J, Dewar AL, et al. Dietary fibre and the occurrence of gut symptoms in cystic fibrosis. Arch Dis Child 1997;76:35–7.

[160] Farrell P, Mischler EH, Sondel S, et al. Predigested formula for infants with cystic fibrosis. J Am Diet Assoc 1987;93:1353–6.

[161] Ellis L, Kalnins D, Corey M, Brennan J, Pencharz P, Durie P. Do infants with cystic fibrosis need a protein hydrolysate formula? A prospective, randomized, comparative study. J Pediatr 1998;132:270–6.

[162] Hill SM, Phillips AD, Mearns M, Walker-Smith JA. Cows' milk sensitive enteropathy in cystic fibrosis. Arch Dis Child 1989;64:1251–5.

[163] Vic P, Ategbo S, Gottrand F, et al. Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Arch Dis Child 1997;76:437–40.

[164] Reilly JJ, Ralston JM, Paton JY, et al. Energy balance during acute exacerbations in children with cystic fibrosis. Eur Respir J 1999;13:804–9.

[165] Burdet L, Huglo O, Aubert JD, Schutz Y, Roulet M, Fitting JW. Effect of elective antibiotic therapy on resting energy expenditure and inflammation in cystic fibrosis. Eur J Pediatr 1999;158:71–6.

[166] Doring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against *Pseudomonas aeruginosa* in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749–67.

[167] Atkinson SN. A comparative study of enzyme activity acid resistance and dissolution characteristics of four enteric coated microsphere preparations of pancreatic enzymes. Eur J Clin Res 1991;1:37–45.

[168] Brady MS, Rickard KA, Yu PL, et al. Effectiveness and safety of small vs. large doses of enteric coated pancreatic enzymes in reducing steatorrhoea in children with cystic fibrosis: a randomized prospective study. Pediatr Pulmonol 1991;10:79–85.

[169] Beker LT, Fink RJ, Shamas FH, et al. Comparison of weight based dosages of enteric-coated microtablet enzyme preparations in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1994;19:191–7.

[170] Sinaasappel M, Swart GR, Hoekstra JH, et al. Double blind, cross over study to prove the equivalence of Creon 10,000 minimicrospheres versus Creon 8000 microspheres in patients with cystic fibrosis. Pediatr Pulmonol ; Suppl :358, P 1998;17:536.

[171] Chazalette JP. A double blind placebo controlled trial of a pancreatic enzyme formulation (Panzytrat 25,000) in the treatment of impaired lipid digestion in patients with cystic fibrosis. Drug Invest 1993;5:274–80.

[172] Bowler IM, Wolfe SP, Owens HM, Sheldon TA, Littlewood JM, Walters MP. A double blind lipase for lipase comparison of a high and standard pancreatic enzyme preparation in cystic fibrosis. Arch Dis Child 1993;68:227–30.

[173] Taylor CJ, McGaw J, Ghosal S, et al. Evaluation of Creon 25,000 compared to standard lipase pancreatic enzyme supplementation in cystic fibrosis patients. Israel J Med Sci 1996;32:S220.

[174] Durie PR, Kalnins D, Ellis L. Uses and abuses of enzyme therapy in cystic fibrosis. J Roy Soc Med 1998;91(Suppl 34):2–13.

[175] Committee on Safety of Medicines. Report of the Pancreatic Enzymes Working Party, London. 1995.

[176] Littlewood JM. Implications of the Committee on Safety of Medicines 10,000 IU lipase/kg/day recommendation for use of pancreatic enzymes in cystic fibrosis. Arch Dis Child 1996;74:466–8.

[177] Anthony H, Collins CE, Davidson G, et al. Pancreatic replacement therapy in cystic Fibrosis: Australian Guidelines. J Paediatr Child Health 1999;35:125–9.

[178] Littlewood JM. Update on intestinal strictures. J R Soc Med 1999;92(Suppl.37):41–9.

[179] Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics 1986;78:473–9.

[180] Malfroot A, Dab I. New insights into gastrointestinal reflux in cystic fibrosis by longitudinal follow-up. Arch Dis Child 1991;66:1339–45.

[181] Heine RG, Button BM, Olinsky A, et al. Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis. Arch Dis Child 1998;78:44–8.

[182] Ledson MJ, Tran J, Walshaw MJ. Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. J Roy Soc Med 1998;91(Suppl):7–9.

[183] Lloyd-Still JD. Cystic Fibrosis, Crohn's disease, biliary abnormalities and cancer. J Pediatr Gastroenterol Nutr 1990;11:434–7.

[184] Gross V, Schoelmerich J, Denzel K, et al. Relapsing pancreatitis as an initial manifestation of cystic fibrosis in young man with cystic fibrosis. Int J Pancreatol 1989;4:221–8.

[185] Colombo C, Battezzati PM, Strazzabosco M, et al. Liver and biliary problems in cystic fibrosis. Semin Liver Dis 1998;18:227–35.

[186] Chamarthy LM, Reinstein LJ, Schnapf B, et al. Desensitisation to pancreatic enzyme intolerance in a child with cystic fibrosis. Pediatrics 1998;102:e13.

[187] Gow R, Bradbear R, Francis P, et al. Comparative study of varying regimens to improve steatorrhoea and creatorrhoea in cystic fibrosis: effectiveness of an enteral coated preparation with and without antacids and cimetidine. Lancet 1981;11:1071–4.

[188] Heijerman HG, Lamers CB, Dijkman JH, et al. Ranitidine compared with the dimethylprostaglandin E2 analogue enprostil as adjunct to pancreatic enzyme replacement in adult cystic fibrosis. Scand J Gastrenterol Suppl 1990;178:26–31.

[189] Heijerman RG, Lamers CB, Bakker W, et al. Improvement of fecal fat excretion after addition of omeprazole to pancrease in cystic fibrosis is related to residual exocrine function of the pancreas. Dig Dis Sci 1993;38:1–6.

[190] Hendriks JJE, Wesseling GJ, et al. Lansoprazole therapy in young CF patients improved fat absorption, bone mineral content and hyperinflation. Nether J Med 1999;54(Suppl):S68.

[191] Smith LJ, Lacaille F, Lepage G, et al. Taurine decreases fecal fatty acid and sterol excretion in cystic fibrosis. A randomized double blind trial. Am J Dis Child 1991;145:1401–4.

[192] Wiersbitzky S, Ballke EH, Wolf E, et al. Uric acid serum concentrations in CF children after pancreatic enzyme supplementation. Paediatrie Grenzgebiete 1989;28:171–3.

[193] Couper R, Lichtman S, Cleghorn G, et al. Serum immunoglobulin G directed against porcine trypsin in pancreatic insufficient cystic fibrosis patients receiving pancreatic enzyme supplements. Pancreas 1991;6:558–63.

[194] Lee J, Ip W, Durie P. Is fibrosing colonopathy an immune mediated disease? Arch Dis Child 1997;77:66–70.

[195] Lipkin GW, Vickers DW. Allergy in cystic fibrosis nurses to pancreatic extract. Lancet 1987;i:392.

[196] Twarog FJ, Weinstein SF, Khaw K-T, et al. Hypersensitivity to pancreatic extracts in parents of patients with cystic fibrosis. J Allergy Clin Immunol 1997;59:35–40.

[197] Smyth RL, van Veltzen D, Smyth AR, et al. Strictures of the ascending colon in cystic fibrosis and high strength pancreatic enzymes. Lancet 1994;343:85–6.

[198] Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-controlled study. Lancet 1995;346:1247–51.

[199] FitzSimmons SC, Burkhart GA, Borowitz D, et al. High dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336:1283–9.

[200] Jones R, Franklin K, Spicer R, Berry J. Colonic strictures in children with cystic fibrosis on low strength pancreatic enzymes. Lancet 1995;346:1230.

[201] Ramsden WH, Moya EF, Littlewood JM. Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis. Arch Dis Child 1998;79:339–43.

[202] Powell CJ. Colonic toxicity from pancreatins: a contemporary safety issue. Lancet 1999;353:911–5.

[203] Lloyd-Still JD, Beno DWA, Uhing MR, et al. Pancreatic enzymes and fibrosing colonopathy. Lancet 1999;354:251.

[204] Dodge JA. Colonic wall thickness and pancreatic enzymes in cystic fibrosis. Arch Dis Child 1999;81:97.

[205] van Egmond A, Kosorok MR, Koscik R, Laxova A, Farrell PM. Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr 1996;63:5–52.

[206] Mischler EH, Parrell SW, Farrell PM, Raynor WJ, Lemen RJ. Correction of linoleic acid deficiency in cystic fibrosis. Pediatr Res 1986;20:36–41.

[207] Strandvik B, Hultcrantz R. Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994;14:1–6.

[208] Sigstrom L, Strandvik B. Erythrocyte sodium-potassium transport in cystic fibrosis. Pediatr Res 1992;31:5–7.

[209] Keicher U, Koletzko B, Reinhardt D. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur J Clin Invest 1995;25:915–9.

[210] Kurlandsky LE. The absorption and effect of dietary supplementation with omega-3-fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol 1994;18:211.

[211] Lawrence R, Sorrell T. Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet 1993;342:465–9.

[212] Katz DP, Manner T, Guida L, et al. The use of an intravenous fish oil emulsion enriched with omega-3-fatty acids in patients with CF. Nutrition 1996;12:334–9.

[213] Pasco JA, Henry MJ, Nicholson GC, et al. Vitamin D status of women in the Geelong Osteoporosis Study: association with diet and casual exposure to sunlight. Med J Aust 2001;175:401–5.

[214] Vieth R. Problems with direct 25-hydroxyvitamin D assays, and the target amount of vitamin D nutrition desirable for patients with osteoporosis. Osteoporos Int 2000;11(7):553–5.

[215] Soltanini-Frisk S, Gronowitz E, Andersson H, Strandvik B. Water-miscible tocopherol is not superior to fat-soluble preparation for vitamin E absorption in cystic fibrosis. Acta Paediatr 2001;90:1112–5.

[216] Steinkamp G, von der Hardt H. Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis. J Pediatr 1994;124:244–9.

[217] Walker SA, Gozal D. Pulmonary function correlates in the prediction of long-term weight gain in cystic fibrosis patients with gastrostomy tube feedings. J Pediatr Gastroenterol Nutr 1998;27:53–6.

[218] Stark LJ, Jelalian E, Mulvihill MM, et al. Eating in preschool children with cystic fibrosis and healthy peers: behavioral analysis. Pediatrics 1995;95:210–5.

[219] Smyth R, Walters S. Oral calorie supplements for cystic fibrosis (Cochrane Review). The Cochrane Library Issue 1, Oxford. 2000.

[220] Jelalian E, Stark LJ, Reynolds L, Seifer R. Nutrition intervention for weight gain in cystic fibrosis: a meta analysis. J Pediatr 1998;132:486–92.

[221] Lester LA, Rothberg RM, Dawson G, et al. Supplemental parenteral nutrition in cystic fibrosis. J Parenter Enteral Nutr 1986;102:89–95.

[222] Skeie B, Askanazi J, Rothkopf MM, et al. Improved exercise tolerance with long-term parenteral nutrition in cystic fibrosis. Crit Care Med 1987;15:960–2.

[223] Gebel M, Wagner S, Strassburg CP, et al. Percutaneous sono-

graphic gastrostomy: method, indications, and problems. Am J Gastroenterol 1998;93:941–5.

[224] Williams SG, Ashworth F, McAlweenie A, Poole S, Hodson ME, Westaby D. Percutaneous endoscopic gastrostomy feeding in patients with cystic fibrosis. Gut 1999;44:87–90.

[225] Rosenfeld M, Casey S, Pepe M, Ramsey BW. Nutritional effects of long-term gastrostomy feedings in children with cystic fibrosis. J Am Diet Assoc 1999;99:191–4.

[226] Erskine JM, Lingard CD, Sontag MK, Accurso FJ. Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and non-elemental formula. J Pediatr 1998;132:265–9.

[227] Allen ED, Mick AB, Nicol J, McCoy KS. Prolonged parenteral nutrition for cystic fibrosis patients. Nutr Clin Pract 1995;10:73–9.

[228] Pencharz P, Hill R, Archibald E, Levy L, Newth C. Energy needs and nutritional rehabilitation in undernourished adolescents and young adult patients with CF. J Pediatr Gastroenterol Nutr 1984;3(Suppl 1):147–53.

[229] Alison JA, Donnelly PM, Lennon M, et al. The effect of a comprehensive, intensive inpatient treatment program on lung function and exercise capacity in patients with cystic fibrosis. Phys Ther 1994;74:583–91.

[230] Heijerman HGM, Bakker W, Sterk PJ, Dijkman JH. Oxygen-assisted exercise training in adult cystic fibrosis with pulmonary limitation to exercise. Int J Rehab Res 1991;14:101–15.

[231] Heijerman HGM. Chronic obstructive lung disease and respiratory muscle function: the role of nutrition and exercise training in cystic fibrosis. Respir Med 1993;87(Suppl B):49–51.